MCID: GNT003
MIFTS: 54

Genital Herpes

Categories: Immune diseases, Infectious diseases, Reproductive diseases

Aliases & Classifications for Genital Herpes

MalaCards integrated aliases for Genital Herpes:

Name: Genital Herpes 12 54 42 3 15 62 17 71
Herpes Genitalis 12 43
Genital Herpes Simplex 12
Virus-Genital Herpes 12
Herpes Genitalia 12
Venereal Herpes 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8704
ICD9CM 34 054.1 054.10
MeSH 43 D006558
NCIt 49 C14364
SNOMED-CT 67 33839006
UMLS 71 C0019342

Summaries for Genital Herpes

MedlinePlus : 42 Genital herpes is a sexually transmitted disease (STD) caused by a herpes simplex virus (HSV). It can cause sores on your genital or rectal area, buttocks, and thighs. You can get it from having vaginal, anal, or oral sex with someone who has it. The virus can spread even when sores are not present. Mothers can also infect their babies during childbirth. Symptoms of herpes are called outbreaks. You usually get sores near the area where the virus has entered the body. The sores are blisters which break and become painful, and then heal. Sometimes people do not know they have herpes because they have no symptoms or very mild symptoms. The virus can be more serious in newborn babies or in people with weak immune systems. Repeat outbreaks are common, especially during the first year. Over time, you get them less often and the symptoms become milder. The virus stays in your body for life. There are tests that can diagnose genital herpes. There is no cure. However, medicines can help lessen symptoms, decrease outbreaks, and lower the risk of passing the virus to others. Correct usage of latex condoms can reduce, but not eliminate, the risk of catching or spreading herpes. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex.

MalaCards based summary : Genital Herpes, also known as herpes genitalis, is related to herpes simplex and meningitis, and has symptoms including fever, sores and swollen glands. An important gene associated with Genital Herpes is ACKR1 (Atypical Chemokine Receptor 1 (Duffy Blood Group)), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Famciclovir and Acyclovir have been mentioned in the context of this disorder. Affiliated tissues include genital system, rectum and testes, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 A herpes simplex that results in infection located in genital system, or located in rectum, has material basis in Human herpesvirus 1 or has material basis in Human herpesvirus 2, which is transmitted by sexual contact. The infection has symptom sores, has symptom fever, and has symptom swollen glands.

CDC : 3 Genital herpes is a common sexually transmitted disease (STD) that any sexually active person can get. Most people with the virus don't have symptoms. Even without signs of the disease, herpes can still be spread to sex partners.

Wikipedia : 74 Genital herpes is an infection by the herpes simplex virus (HSV) of the genitals. Most people either... more...

Related Diseases for Genital Herpes

Diseases related to Genital Herpes via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 428, show less)
# Related Disease Score Top Affiliating Genes
1 herpes simplex 31.1 TNFRSF14 TLR2 NECTIN1 IFI16 GYPC CD8A
2 meningitis 30.6 TLR2 IL4 IL18 IL10 CCL5
3 chlamydia 30.4 TLR2 NECTIN1 IL4 IL18 IL10
4 toxoplasmosis 30.4 TLR2 IL4 IL10
5 bacterial vaginosis 30.3 TLR2 PI3 IL4 IL10
6 syphilis 30.3 CD8A CD4 CCR6
7 acquired immunodeficiency syndrome 30.2 IL10 CD4 CCR6 APOE
8 filariasis 30.2 TLR2 IL10 CCL5
9 cervicitis 30.2 TLR2 CD8A CD4
10 neuritis 30.1 IL4 IL10 CCL5 APOE
11 oral candidiasis 30.0 CD8A CD4 CCR6
12 stomatitis 29.9 TLR2 IL4 IL10 CD4
13 dermatitis 29.9 TLR2 IL4 IL18 IL10 CCR6 CCL5
14 immune deficiency disease 29.7 IL4 IL18 IL10 CD80 CD4 CCR6
15 contact dermatitis 29.7 TLR2 IL4 IL18 IL10 CD4
16 anogenital venereal wart 29.6 TLR2 CD8A CD4
17 vaginitis 29.5 TLR2 IL10 CD4 CCR6 CCL5
18 herpes zoster 29.4 TLR2 IL10 GYPC CD8A CD4 APOE
19 bronchopneumonia 29.4 PI3 IL10 CD8A CD4
20 crohn's disease 29.3 TLR2 IL4 IL18 IL10 CD4 CCR6
21 chickenpox 29.2 IL4 IL10 GYPC CD8A CD4 CCR6
22 exanthem 29.2 IL10 CD8A CD4 CCR6
23 autoimmune disease 29.1 TBX21 IL4 IL18 IL10 CD80 CCR6
24 herpetic whitlow 29.1 TNFRSF14 OST4 NECTIN1 ACKR1
25 meningoencephalitis 29.0 IL10 CD8A CD4 CCR6 CCL5
26 listeriosis 28.9 TLR2 TBX21 IL18 IL10 CD8A CD4
27 human immunodeficiency virus infectious disease 28.9 IL4 IL10 CD8A CD80 CD4 CCR6
28 leukemia, chronic lymphocytic 28.8 IL4 IL10 CD8A CD80 CD4 CCR6
29 keratitis, hereditary 28.8 TLR2 IL10 CD8A CD4 CCR6 ACKR1
30 vaginal disease 28.8 TLR2 IL10 CD8A CD4 CCR6 CCL5
31 peripheral nervous system disease 28.8 TLR2 IL4 IL10 CD8A CD4 CCR6
32 skin disease 28.6 TLR2 PI3 IL4 IL18 IL10 CD8A
33 eye disease 28.6 TLR2 IL4 IL10 CD8A CD4 CCR6
34 bacterial infectious disease 28.2 TLR2 PI3 IL18 IL10 CD8A CD80
35 herpes simplex encephalitis 11.6
36 mollaret meningitis 11.4
37 congenital herpes simplex 11.2
38 neonatal herpes 10.7
39 tropical endomyocardial fibrosis 10.6 IL4 IL10
40 spotted fever rickettsiosis 10.5 IL10 CCL5
41 cutaneous leishmaniasis 10.5 TLR2 IL4 IL10
42 neurosyphilis 10.5 TLR2 IL10
43 orofacial granulomatosis 10.5 IL4 IL10 CCL5
44 periapical granuloma 10.5 TLR2 IL4 CCL5
45 autoimmune hepatitis type 1 10.4 IL4 IL10
46 penicillin allergy 10.4 IL4 IL18 IL10
47 acute graft versus host disease 10.4 IL4 IL18 IL10
48 blau syndrome 10.4 TLR2 IL4 IL10
49 paracoccidioidomycosis 10.4 TLR2 IL4 IL10
50 rheumatic heart disease 10.4 TLR2 IL4 IL10
51 aggressive periodontitis 10.4 TLR2 IL4 IL10
52 scrub typhus 10.4 TLR2 IL18 IL10
53 tonsillitis 10.4 TLR2 IL4 IL10
54 brucellosis 10.4 IL4 IL18 IL10
55 silicosis 10.4 IL4 IL18 IL10
56 chronic inflammatory demyelinating polyradiculoneuropathy 10.4 TBX21 IL10 CCL5
57 dengue hemorrhagic fever 10.4 IL4 IL18 IL10
58 polyradiculoneuropathy 10.4 TBX21 IL10 CCL5
59 melioidosis 10.4 TLR2 IL18 IL10
60 esophagitis 10.4 IL4 IL10 CCL5
61 chorioamnionitis 10.4 IL4 IL18 IL10
62 allergic contact dermatitis 10.3 IL4 IL10 CD4
63 bacterial meningitis 10.3 TLR2 IL18 IL10
64 leishmaniasis 10.3 TLR2 IL4 IL18 IL10
65 primary progressive multiple sclerosis 10.3 IL4 IL10 APOE
66 inflammatory bowel disease 18 10.3 IL4 IL10 CCR6
67 egg allergy 10.3 IL4 IL10 CCR6
68 q fever 10.3 TLR2 IL4 IL10 CCL5
69 familial mediterranean fever 10.3 TLR2 IL18 IL10
70 vulvovaginitis 10.3 IL10 CCR6 CCL5
71 food allergy 10.3 TLR2 IL4 IL10
72 bronchiolitis 10.3 TLR2 IL4 IL10 CCL5
73 osteomyelitis 10.3 TLR2 IL4 IL10 CCL5
74 mycoplasma pneumoniae pneumonia 10.3 TLR2 IL4 IL18 IL10
75 lepromatous leprosy 10.3 TLR2 IL4 IL18 IL10
76 leptospirosis 10.3 TLR2 IL4 IL18 IL10
77 trichinosis 10.3 IL4 IL10 CD4
78 takayasu arteritis 10.3 IL18 IL10 CCL5
79 aphthous stomatitis 10.3 TLR2 IL4 IL18 IL10
80 vulvovaginal candidiasis 10.3 TLR2 IL4 CCR6
81 chronic graft versus host disease 10.3 IL10 CD4
82 bronchitis 10.3 TLR2 IL4 IL10 CCL5
83 cervical cancer 10.3
84 visceral leishmaniasis 10.3 TLR2 IL4 IL18 IL10
85 chronic fatigue syndrome 10.3 IL4 IL10 CCL5
86 peanut allergy 10.3 IL4 IL10 CCR6
87 alcoholic hepatitis 10.3 TLR2 IL18 IL10
88 pulmonary tuberculosis 10.3 TLR2 IL4 IL18 IL10
89 amebiasis 10.3 TLR2 IL4 CD4
90 periodontitis 10.3 TLR2 IL4 IL18 IL10
91 plasmodium falciparum malaria 10.3 IL4 IL18 IL10
92 perinatal necrotizing enterocolitis 10.3 TLR2 IL10 CCR6
93 schistosomiasis 10.3 IL4 IL10 CD80 CCL5
94 rosacea 10.3 TLR2 IL18 CCR6
95 interstitial lung disease 10.3 IL4 IL18 IL10 CCL5
96 necrotizing gastritis 10.3 GYPC ACKR1
97 toxic shock syndrome 10.3 TLR2 IL4 IL10
98 stachybotrys chartarum 10.3 IL18 CCL5
99 cysticercosis 10.3 IL18 IL10 CD4
100 allergic rhinitis 10.3 IL4 IL18 IL10 CCL5
101 extrapulmonary tuberculosis 10.2 TLR2 IL10 CD4
102 pulmonary sarcoidosis 10.2 IL18 CCR6 CCL5
103 autoimmune polyendocrine syndrome 10.2 IL18 IL10 CCR6
104 otitis media 10.2 TLR2 IL4 IL10
105 urethritis 10.2
106 hashimoto thyroiditis 10.2 IL4 IL18 IL10 CD80
107 reactive arthritis 10.2 TLR2 IL10 CCR6
108 cryptococcal meningitis 10.2
109 neurogenic bladder 10.2
110 laryngotracheitis 10.2 GYPC ACKR1
111 autoimmune vasculitis 10.2 IL4 CD4 CCR6
112 ileitis 10.2 TLR2 IL10 CCR6 CCL5
113 gingivitis 10.2 TLR2 IL4 IL18 IL10 CCL5
114 filarial elephantiasis 10.2 TLR2 IL4 IL10 CD4
115 proteasome-associated autoinflammatory syndrome 1 10.2 TLR2 IL4 IL18 IL10 CCL5
116 suppressor of tumorigenicity 3 10.2
117 chancroid 10.2
118 trypanosomiasis 10.2 TLR2 IL4 IL18 IL10 CCL5
119 peritonitis 10.2 TLR2 IL4 IL18 IL10 CCL5
120 allergic asthma 10.2 TLR2 IL4 IL18 IL10 CCL5
121 mastitis 10.2 TLR2 IL18 CCR6 CCL5
122 igg4-related disease 10.2 IL4 CD4 CCR6
123 bacterial sepsis 10.2 TLR2 IL18 IL10 CCR6
124 keratoconjunctivitis sicca 10.2 IL4 CD4 CCR6
125 hyper ige recurrent infection syndrome 1 10.2 IL10 CD4 CCR6
126 suppurative lymphadenitis 10.1 CD4 CCR6
127 chlamydia pneumonia 10.1 TLR2 IL10 CD4 APOE
128 lymphopenia 10.1 IL4 IL18 IL10 CCR6
129 bullous skin disease 10.1 CD4 CCR6 CCL5
130 human immunodeficiency virus type 1 10.1
131 aseptic meningitis 10.1
132 neutropenia 10.1
133 cytokine deficiency 10.1
134 cerebral palsy 10.1 IL18 IL10 APOE
135 arteriosclerosis 10.1 IL4 IL18 IL10 CCL5 APOE
136 oral cavity cancer 10.1 TLR2 IL4 IL18 CCR6
137 thrombocytopenic purpura, autoimmune 10.1 IL18 CD4 CCR6
138 cork-handlers' disease 10.1 CD8A CD4
139 echinococcosis 10.1 TLR2 IL10 CD8A
140 erythema multiforme 10.1
141 myelitis 10.1
142 syphilitic meningitis 10.1 CD8A CD4
143 vogt-koyanagi-harada disease 10.1 TLR2 IL10 CD8A
144 ventilation pneumonitis 10.1 CD8A CD4
145 kawasaki disease 10.1 IL4 IL10 CD4
146 folliculitis 10.1 IL4 CD4 CCR6 CCL5
147 mikulicz disease 10.1 IL4 IL10 CD4 CCR6
148 tuberculoid leprosy 10.1 IL4 IL10 CD4 CCR6
149 diffuse infiltrative lymphocytosis syndrome 10.0 CD8A CD4
150 autoimmune lymphoproliferative syndrome, type iia 10.0 CD8A CD4
151 chronic conjunctivitis 10.0 IL4 IL10 CD4 CCR6
152 nut allergy 10.0 IL4 IL10 CD4 CCR6
153 intestinal schistosomiasis 10.0 IL4 IL10 CD4 CCR6
154 autoimmune gastritis 10.0 IL4 IL10 CD4 CCR6
155 chromosome 14q11-q22 deletion syndrome 10.0 CD8A CD4
156 balanitis 10.0
157 pemphigoid gestationis 10.0
158 hyperuricemia 10.0
159 secondary syphilis 10.0
160 rubella 10.0
161 cervix uteri carcinoma in situ 10.0
162 cervical intraepithelial neoplasia 10.0
163 meningitis and encephalitis 10.0
164 diabetes mellitus, insulin-dependent, 23 10.0 CD8A CD4
165 gingival disease 10.0 TLR2 IL10 CD4 CCR6
166 chagas disease 10.0 TLR2 IL4 IL10 CD4 CCL5
167 diabetes mellitus, ketosis-prone 10.0
168 lymphogranuloma venereum 10.0
169 candidiasis 10.0
170 trichomoniasis 10.0
171 in situ carcinoma 10.0
172 granuloma inguinale 10.0
173 eczema herpeticum 10.0
174 encephalitis 10.0
175 cytomegalovirus infection 10.0
176 psoriatic arthritis 10.0 TLR2 IL4 IL18 IL10 CCR6
177 dysentery 10.0 TLR2 IL10 CD4 CCR6
178 invasive aspergillosis 10.0 TLR2 IL10 CD4 CCR6
179 bird fancier's lung 10.0 CD8A CD4
180 early yaws 10.0 CD8A CD4
181 colitis 10.0 TLR2 IL4 IL18 IL10 CCR6
182 lymphadenitis 10.0 IL18 IL10 CD4 CCR6
183 corticosteroid allergy 10.0 IL4 CD8A CD4
184 parapsoriasis 10.0 CD8A CD4
185 superficial basal cell carcinoma 10.0 TLR2 CD8A CD4
186 combined thymoma 10.0 IL10 CD8A CD4
187 norwegian scabies 10.0 CD8A CD4
188 chorioretinitis 10.0 IL10 CD8A CD4
189 fungal meningitis 10.0 IL10 CD8A CD4
190 macs syndrome 10.0 IL10 CD8A CD4
191 orchitis 10.0 IL10 CD8A CD4
192 congenital toxoplasmosis 10.0 IL10 CD8A CD4
193 hydrocephalus 10.0 TLR2 IL18 IL10 APOE
194 fallopian tube disease 10.0 TLR2 CD8A CD4
195 penile disease 10.0 TLR2 CD8A CD4
196 acute myocarditis 10.0 IL10 CD8A CD4
197 ehrlichiosis 9.9 IL10 CD8A CD4
198 variola major 9.9 CD8A CD4
199 farmer's lung 9.9 PI3 CD8A CD4
200 lymphoma, mucosa-associated lymphoid type 9.9 TLR2 CD80 CD4 CCR6
201 granulomatosis with polyangiitis 9.9 TLR2 CD80 CD4 CCR6
202 dengue disease 9.9 CD8A CCR6 CCL5
203 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
204 lymphocytic leukemia 9.9
205 diarrhea 9.9
206 urticaria 9.9
207 cystitis 9.9
208 impotence 9.9
209 constipation 9.9
210 phimosis 9.9
211 primary syphilis 9.9
212 radiculopathy 9.9
213 nervous system disease 9.9
214 molluscum contagiosum 9.9
215 48,xyyy 9.9
216 postherpetic neuralgia 9.9
217 acute liver failure 9.9
218 thrombotic microangiopathy 9.9
219 acquired metabolic disease 9.9 IL10 CD4 CCR6 APOE
220 follicular mucinosis 9.9 CD8A CD4
221 tertiary syphilis 9.9 CD8A CD4
222 immunodeficiency with hyper-igm, type 3 9.9 CD8A CD80 CD4
223 aspergillosis 9.9 TLR2 IL4 IL18 IL10 CCR6 CCL5
224 granulomatous hepatitis 9.9 CD8A CD4
225 mast cell neoplasm 9.9 CD8A CD80 CD4
226 yellow fever 9.9 IL4 CD8A CCR6 CCL5
227 aplastic anemia 9.9 TBX21 IL4 IL18 IL10 CD4
228 relapsing-remitting multiple sclerosis 9.9 IL4 IL18 IL10 CCR6 CCL5 APOE
229 acute cystitis 9.9 TLR2 IL18 IL10 CD4 CCR6
230 metal allergy 9.9 IL4 IL10 CD8A CD4
231 nickel allergic contact dermatitis 9.9 IL4 IL10 CD8A CD4
232 taeniasis 9.9 IL4 IL10 CD8A CD4
233 spongiotic dermatitis 9.9 CD8A CD4 CCR6
234 poliomyelitis 9.9 IL4 IL10 CD8A CD4
235 esophageal candidiasis 9.8 CD8A CD4 CCR6
236 viral pneumonia 9.8 IL10 CD8A CD4 CCL5
237 pneumonic plague 9.8 TLR2 IL10 CD8A CD4
238 plague 9.8 TLR2 IL10 CD8A CD4
239 blastomycosis 9.8 CD8A CD4 CCR6
240 central nervous system vasculitis 9.8 CD8A CD4 CCR6
241 tularemia 9.8 TLR2 IL18 CD8A CD4
242 t-cell adult acute lymphocytic leukemia 9.8 CD8A CD4 CCR6
243 epidemic typhus 9.8 TLR2 CD8A CD4 CCL5
244 adult acute lymphocytic leukemia 9.8 CD8A CD4 CCR6
245 autoimmune glomerulonephritis 9.8 CD8A CD4 CCR6
246 childhood type dermatomyositis 9.8 CD8A CD4 CCR6
247 pneumocystosis 9.8 CD8A CD4 CCR6
248 histoplasmosis 9.8 CD8A CD4 CCR6
249 t cell deficiency 9.8 CD8A CD4 CCR6
250 immunoglobulin alpha deficiency 9.8 CD8A CD4 CCR6
251 omenn syndrome 9.8 IL4 IL10 CD8A CD4
252 brachydactyly, type c 9.8 CD8A CD4 CCR6
253 nail disease 9.8 CD8A CD4 CCR6
254 progressive multifocal leukoencephalopathy 9.8 CD8A CD4 CCR6
255 thymus gland disease 9.8 CD8A CD4 CCR6
256 thymus cancer 9.8 CD8A CD4 CCR6
257 salivary gland disease 9.8 CD8A CD4 CCR6
258 extrinsic allergic alveolitis 9.8 PI3 IL18 IL10 CD80 CCR6 CCL5
259 annular erythema 9.8
260 lichen sclerosus et atrophicus 9.8
261 benign chronic pemphigus 9.8
262 preterm premature rupture of the membranes 9.8
263 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.8
264 sexual disorder 9.8
265 cutaneous t cell lymphoma 9.8
266 physical disorder 9.8
267 pelvic inflammatory disease 9.8
268 viral meningitis 9.8
269 nasopharyngitis 9.8
270 hypospadias 9.8
271 cauda equina syndrome 9.8
272 optic neuritis 9.8
273 common variable immunodeficiency 9.8
274 varicocele 9.8
275 vulva cancer 9.8
276 hepatitis a 9.8
277 acute leukemia 9.8
278 squamous cell papilloma 9.8
279 squamous cell carcinoma 9.8
280 vulva squamous cell carcinoma 9.8
281 pharyngitis 9.8
282 papilloma 9.8
283 cervix carcinoma 9.8
284 anuria 9.8
285 proctitis 9.8
286 vaccinia 9.8
287 central nervous system disease 9.8
288 verrucous carcinoma 9.8
289 vaginal discharge 9.8
290 vulvitis 9.8
291 polyradiculopathy 9.8
292 infertility 9.8
293 severe combined immunodeficiency 9.8
294 myocarditis 9.8
295 scabies 9.8
296 intestinal obstruction 9.8
297 actinomycosis 9.8
298 neuromyelitis optica 9.8
299 lichen planus 9.8
300 diabetes mellitus 9.8
301 keratoconjunctivitis 9.8
302 congenital syphilis 9.8
303 hypereosinophilic syndrome 9.8
304 herpes virus antenatal infection 9.8
305 neuromyelitis optica spectrum disorder 9.8
306 splenomegaly 9.8
307 autonomic dysfunction 9.8
308 back pain 9.8
309 chronic pain 9.8
310 headache 9.8
311 gastric adenocarcinoma and proximal polyposis of the stomach 9.8
312 transient pseudohypoaldosteronism 9.8
313 lymphatic system cancer 9.8 CD8A CD4 CCR6
314 common cold 9.8 TLR2 IL4 IL10 CD4 CCR6 CCL5
315 pleural disease 9.8 CD8A CD4 CCR6
316 epidermodysplasia verruciformis 1 9.8 CD8A CD4 CCR6
317 west nile encephalitis 9.8 CD8A CD4
318 cytomegalovirus retinitis 9.7 IL10 IFNL4 CD8A CD4
319 allergic hypersensitivity disease 9.7 TLR2 IL4 IL10 CD4 CCR6 CCL5
320 vitiligo-associated multiple autoimmune disease susceptibility 1 9.7 CD8A CD4 CCR6
321 blepharitis 9.7 IL4 CD8A CD4 CCR6
322 lichen disease 9.7 IL4 CD8A CD4 CCR6
323 pneumonic tularemia 9.7 TLR2 CD8A CD4 CCR6
324 mature b-cell neoplasm 9.7 CD8A CD4 CCR6
325 blood coagulation disease 9.7 CD8A CD4 CCR6
326 streptococcus pneumonia 9.7 TLR2 IL4 IL10 CD8A CD4
327 pneumonia 9.7 TLR2 IL4 IL18 IL10 CD8A CCL5
328 dacryoadenitis 9.7 IL10 CD8A CD4 CCR6
329 thrombocytopenia due to platelet alloimmunization 9.7 IL10 CD8A CD4 CCR6
330 primary thrombocytopenia 9.7 IL10 CD8A CD4 CCR6
331 neurosarcoidosis 9.7 CD8A CD4
332 temporal arteritis 9.7 CD8A CD4 CCR6 CCL5
333 autoimmune disease of blood 9.7 IL10 CD8A CD4 CCR6
334 panuveitis 9.7 IL10 CD8A CD4 CCR6
335 autoimmune disease of urogenital tract 9.7 IL10 CD8A CD4 CCR6
336 cellulitis 9.7 IL10 CD8A CD4 CCR6
337 spinal cord disease 9.7 IL10 CD8A CD4 CCR6
338 mucocutaneous leishmaniasis 9.7 IL4 IL10 CD8A CD4 APOE
339 x-linked recessive disease 9.7 IL10 CD8A CD4 CCR6
340 systemic scleroderma 9.7 IL4 CD8A CD4 CCR6
341 blood platelet disease 9.7 IL10 CD8A CD4 CCR6
342 arthritis 9.7 TLR2 IL4 IL18 IL10 CD80 CCR6
343 autoimmune disease of cardiovascular system 9.7 CD8A CD80 CD4 CCR6
344 myocardial infarction 9.7 TLR2 IL4 IL18 IL10 CCL5 APOE
345 sialadenitis 9.7 CD8A CD80 CD4 CCR6
346 cd3zeta deficiency 9.6 CD8A CD4
347 lacrimal apparatus disease 9.6 IL4 IL10 CD8A CD4 CCR6
348 cryptococcosis 9.6 IL4 IL10 CD8A CD4 CCR6
349 autoimmune disease of endocrine system 9.6 IL4 IL10 CD8A CD4 CCR6
350 paranasal sinus disease 9.6 IL4 IL10 CD8A CD4 CCR6
351 b cell deficiency 9.6 IL4 IL10 CD8A CD4 CCR6
352 combined t cell and b cell immunodeficiency 9.6 IL4 IL10 CD8A CD4 CCR6
353 neuromuscular junction disease 9.6 IL4 IL10 CD8A CD4 CCR6
354 autoimmune disease of gastrointestinal tract 9.6 IL4 IL10 CD8A CD4 CCR6
355 hypotrichosis 1 9.6 IL4 IL10 CD8A CD4 CCR6
356 uveal disease 9.6 IL4 IL10 CD8A CD4 CCR6
357 collagen disease 9.6 IL4 IL10 CD8A CD4 CCR6
358 hair disease 9.6 IL4 IL10 CD8A CD4 CCR6
359 chediak-higashi syndrome 9.6 IL4 IL10 CD8A CD4 CCR6
360 viral encephalitis 9.6 IL10 CD8A CD4 CCR6 CCL5
361 lymphatic system disease 9.6 IL4 IL10 CD8A CD4 CCR6
362 sezary's disease 9.6 IL4 IL10 CD8A CD4 CCR6
363 middle ear disease 9.6 TLR2 IL10 CD8A CD4 CCR6
364 anus disease 9.6 TLR2 IL10 CD8A CD4 CCR6
365 rectal disease 9.6 TLR2 IL10 CD8A CD4 CCR6
366 leukocyte disease 9.6 IL4 IL10 CD8A CD4 CCR6
367 bacterial pneumonia 9.6 TLR2 IL10 CD8A CD4 CCR6
368 corneal disease 9.6 TLR2 IL10 CD8A CD4 CCR6
369 neuromuscular disease 9.5 IL10 CD8A CD4 CCR6
370 glucose metabolism disease 9.5 IL10 CD8A CD4 CCR6 APOE
371 lung disease 9.5 TLR2 PI3 IL4 IL18 IL10 CD8A
372 immunodeficiency 18 9.5 CD8A CD4
373 muscular disease 9.5 IL4 IL10 CD8A CD4 CCR6
374 viral infectious disease 9.5 TLR2 IL4 IL18 IL10 CD4 CCR6
375 primary systemic mycosis 9.4 TLR2 IL4 IL10 CD8A CD4 CCR6
376 herpangina 9.4 TLR2 IL4 IL10 CD8A CD4 CCR6
377 splenic disease 9.4 TLR2 IL4 IL10 CD8A CD4 CCR6
378 coccidiosis 9.4 TLR2 IL4 IL10 CD8A CD4 CCR6
379 opportunistic mycosis 9.4 TLR2 IL4 IL10 CD8A CD4 CCR6
380 lymph node disease 9.4 TLR2 IL4 IL10 CD8A CD4 CCR6
381 commensal bacterial infectious disease 9.4 TLR2 IL4 IL10 CD8A CD4 CCR6
382 testicular disease 9.4 TLR2 IL4 IL10 CD8A CD4 CCR6
383 leprosy 3 9.4 TLR2 IL4 IL10 CD8A CD4 CCR6
384 demyelinating disease 9.4 IL4 IL10 CD8A CD4 CCR6 CCL5
385 upper respiratory tract disease 9.4 TLR2 IL4 IL10 CD8A CD4 CCR6
386 diabetes mellitus, noninsulin-dependent 9.4 TLR2 IL4 IL18 IL10 CD4 CCR6
387 salmonellosis 9.4 TLR2 IL18 IL10 CD8A CD4 CCR6
388 connective tissue disease 9.4 TLR2 IL4 IL10 CD8A CD4 CCR6
389 autoimmune disease of eyes, ear, nose and throat 9.4 TBX21 IL4 IL10 CD8A CD4 CCR6
390 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 9.4 TBX21 IL4 IL10 CD8A CD4 CCR6
391 psoriasis 9.4 TLR2 PI3 IL4 IL18 IL10 CD4
392 body mass index quantitative trait locus 11 9.4 TLR2 IL4 IL18 IL10 CD4 CCR6
393 sarcoidosis 1 9.3 IL18 CD8A CD80 CD4 CCR6 CCL5
394 rheumatoid arthritis 9.3 TLR2 IL4 IL18 IL10 CD80 CD4
395 myeloma, multiple 9.3 IL4 IL10 CD8A CD80 CD4 CCR6
396 lymphoma, non-hodgkin, familial 9.3 IL4 IL10 CD8A CD80 CD4 CCR6
397 parasitic protozoa infectious disease 9.3 TLR2 IL4 IL10 CD8A CD4 CCR6
398 conjunctival disease 9.3 TLR2 IL4 IL10 CD8A CD4 CCR6
399 nasal cavity disease 9.3 TLR2 IL4 IL10 CD8A CD4 CCR6
400 nose disease 9.3 TLR2 IL4 IL10 CD8A CD4 CCR6
401 extrinsic cardiomyopathy 9.3 TLR2 IL4 IL18 IL10 CD8A CD4
402 hypersensitivity reaction type iv disease 9.3 TLR2 IL4 IL18 IL10 CD8A CD4
403 leukemia, acute myeloid 9.3 IL4 IL10 CD8A CD80 CD4 CCR6
404 chronic mucocutaneous candidiasis 9.3 TLR2 IL4 IL18 IL10 CD8A CD4
405 mycobacterium tuberculosis 1 9.3 TLR2 IL4 IL18 IL10 CD8A CD4
406 parasitic helminthiasis infectious disease 9.2 TLR2 TBX21 IL4 IL10 CD8A CD4
407 autoimmune disease of musculoskeletal system 9.2 TLR2 IL4 IL10 CD8A CD80 CD4
408 pfeiffer syndrome 9.2 OST4 CD8A CD4 CCR6
409 hypertension, essential 9.2 TLR2 IL4 IL18 IL10 CD8A CD4
410 asthma 9.2 TLR2 TBX21 IL4 IL18 IL10 CD80
411 pulmonary fibrosis, idiopathic 9.1 TLR2 IL4 IL18 IL10 CD8A CD4
412 cone-rod dystrophy 2 9.1 TNFRSF14 NECTIN1 CD8A CD4 ACKR1
413 respiratory allergy 9.1 TLR2 TBX21 IL4 IL10 CD8A CD4
414 bronchial disease 9.1 TLR2 TBX21 IL4 IL10 CD8A CD4
415 bone inflammation disease 9.1 TLR2 IL4 IL18 IL10 CD8A CD80
416 behcet syndrome 9.1 TLR2 IL4 IL18 IL10 CD8A CD80
417 diabetes mellitus, insulin-dependent 9.0 TLR2 IL4 IL18 IL10 CD8A CD80
418 acute retinal necrosis syndrome 9.0 TNFRSF14 NECTIN1 GYPC CD8A CD4
419 inflammatory bowel disease 9.0 TLR2 TBX21 IL4 IL18 IL10 CD8A
420 primary bacterial infectious disease 8.9 TLR2 IL4 IL18 IL10 CD8A CD80
421 pulmonary disease, chronic obstructive 8.9 TLR2 PI3 IL4 IL10 CD8A CD80
422 autoimmune disease of central nervous system 8.9 TLR2 TBX21 IL4 IL10 CD8A CD80
423 celiac disease 1 8.9 TLR2 TBX21 IL4 IL18 IL10 CD8A
424 multiple sclerosis 8.7 TLR2 IL4 IL18 IL10 CD8A CD80
425 immune system disease 8.7 TLR2 TBX21 IL4 IL18 IL10 CD8A
426 dermatitis, atopic 8.7 TLR2 TBX21 IL4 IL18 IL10 CD8A
427 malaria 8.7 TLR2 IL4 IL18 IL10 GYPC CD8A
428 systemic lupus erythematosus 8.5 TLR2 TBX21 IL4 IL18 IL10 IFI16

Comorbidity relations with Genital Herpes via Phenotypic Disease Network (PDN): (showing 1, show less)


Acute Cystitis

Graphical network of the top 20 diseases related to Genital Herpes:



Diseases related to Genital Herpes

Symptoms & Phenotypes for Genital Herpes

Symptoms:

12 (showing 3, show less)
  • fever
  • sores
  • swollen glands

UMLS symptoms related to Genital Herpes:


fever, pruritus, pelvic pain

MGI Mouse Phenotypes related to Genital Herpes:

45 (showing 4, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 APOE CCL5 CCR6 CD4 CD80 CD8A
2 digestive/alimentary MP:0005381 9.86 APOE CD4 IL10 IL18 IL4 TBX21
3 immune system MP:0005387 9.8 ACKR1 APOE CCL5 CCR6 CD4 CD80
4 integument MP:0010771 9.28 APOE CD4 CD8A IFNE IL10 IL18

Drugs & Therapeutics for Genital Herpes

Drugs for Genital Herpes (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 38, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Famciclovir Approved, Investigational Phase 4 104227-87-4 3324
2
Acyclovir Approved Phase 4 59277-89-3 2022
3
Metronidazole Approved Phase 4 443-48-1 4173
4
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
5
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
6 Reverse Transcriptase Inhibitors Phase 4
7 Denatonium Phase 4
8 Anti-HIV Agents Phase 4
9 Anti-Infective Agents Phase 4
10 Antioxidants Phase 4
11 Protective Agents Phase 4
12 Central Nervous System Depressants Phase 4
13 Anti-Bacterial Agents Phase 4
14 Antibiotics, Antitubercular Phase 4
15 Antiparasitic Agents Phase 4
16 Antiprotozoal Agents Phase 4
17
Halofantrine Approved Phase 3 69756-53-2 37393
18
Aluminum sulfate Approved Phase 3 10043-01-3
19 Vaccines Phase 3
20 Immunologic Factors Phase 3
21 polysaccharide-K Phase 3
22 Adjuvants, Immunologic Phase 3
23 interferons Phase 3
24 Monophosphoryl lipid A Phase 3
25 Radiation-Protective Agents Phase 3
26 Interferon Inducers Phase 3
27 Pritelivir Investigational Phase 2 348086-71-5
28 Saponin QA-21V1 Phase 2
29 Antiviral Agents Phase 2
30 valacyclovir Phase 2
31 Antibodies, Monoclonal Phase 2
32 Antibodies Phase 2
33 Immunoglobulins Phase 2
34 Lecithin Phase 2
35
Glutamic acid Approved, Nutraceutical Phase 1 56-86-0 33032
36 Pharmaceutical Solutions Phase 1
37
Histidine Investigational, Nutraceutical Phase 1 71-00-1 6274
38 Anti-Retroviral Agents

Interventional clinical trials:

(showing 90, show less)
# Name Status NCT ID Phase Drugs
1 Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission Unknown status NCT00495716 Phase 4 acyclovir;acyclovir
2 A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding Completed NCT00129818 Phase 4 Famciclovir
3 An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients Completed NCT00158860 Phase 4 Valaciclovir;Placebo
4 A Randomized, Multicenter, Double-blind Study to Compare the Efficacy of Single-day Treatment (1000 mg b.i.d.) With Famciclovir Compared to That of Placebo in Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Immunocompetent Black Patients Completed NCT00477334 Phase 4 Famciclovir;Placebo
5 A Study to Determine the Safety and Efficacy of Famciclovir in the Episodic and Suppressive Treatment of Recurrent Genital Herpes (RGH). The Study Will Also Evaluate Quality of Life and Patient Satisfaction Completed NCT00219310 Phase 4 Famciclovir
6 Effect of Tenofovir on Genital HSV Shedding: a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01448616 Phase 4 TDF;Placebo Vaginal Gel;Vaginal TFV Gel;Placebo Tablets
7 A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of Acyclovir on Rapidly Cleared Herpes Simplex Virus Type 2 Genital Reactivation Episodes in Herpes Simplex Virus-2 Seropositive Adults Completed NCT00723229 Phase 4 acyclovir
8 A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Acyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults Completed NCT00362297 Phase 4 acyclovir;valacyclovir
9 A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons Completed NCT00527618 Phase 4 valacyclovir;acyclovir
10 A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Valacyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults Completed NCT01346475 Phase 4 valacyclovir;Valacyclovir
11 The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection Completed NCT00306293 Phase 4 valacyclovir
12 Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH Completed NCT00116844 Phase 4 Valaciclovir;Placebo
13 Effects of Melatonin in the Treatment of Genital Herpes Recruiting NCT03831165 Phase 4 Acyclovir 400 MG
14 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Recruiting NCT02042287 Phase 4 Metronidazole
15 An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons With CD4+ Lymphocyte Count <100 Cells/mm3. Terminated NCT00079911 Phase 4 valacyclovir hydrochloride
16 An International, Randomized, Double-Blind, Placebo-Controlled Study of Valacyclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects Unknown status NCT00005663 Phase 3 Valacyclovir hydrochloride
17 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
18 Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes Completed NCT00171990 Phase 3 Famciclovir
19 A Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Patient-initiated Famciclovir 1000 mg b.i.d. x 1 Day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults With Recurrent Genital Herpes Completed NCT00306787 Phase 3 Famciclovir;Valacyclovir;Placebo matching famciclovir;Placebo matching valacyclovir
20 A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 125 mg Comparing to Aciclovir 200 mg in Patients With Active Recurrent Genital Herpes Completed NCT01281007 Phase 3 Famciclovir;Aciclovir
21 Safety of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) With MPL & Its Efficacy to Prevent Genital Herpes Disease in HSV Positive or Negative Consorts of Subjects With Genital Herpes Disease Completed NCT00699764 Phase 3
22 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir for the Reduction of HIV Acquisition Among High-Risk HSV-2 Seropositive, HIV Seronegative Individuals Completed NCT00076232 Phase 3 Acyclovir;Acyclovir placebo
23 Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV Transmission Among HIV-Discordant Couples Completed NCT00194519 Phase 3 Generic acyclovir;Placebo
24 An International Multi-centre, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of 0.5% and 2% PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection Completed NCT00262106 Phase 3 PRO 2000/5;Placebo
25 Study to Evaluate the Safety of GSK Biologicals' Herpes Simplex Candidate Vaccine (gD2t) With MPL in HSV Seropositive or Seronegative Subjects Without Genital Herpes Disease Completed NCT00698568 Phase 3
26 Open-label Study of ASP2151 in Herpes Simplex Patients Completed NCT02209324 Phase 3 ASP2151
27 A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who Are HSV-1 and -2 Seronegative Completed NCT00057330 Phase 3
28 A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples Completed NCT00001649 Phase 3 Valaciclovir
29 Phase III Study of ASP2151 in Herpes Simplex Patients ― A Double-blind, Placebo-controlled Study ― Completed NCT01959295 Phase 3 ASP2151;ASP2151 placebo
30 VALacyclovir In Delaying Antiretroviral Treatment Entry Completed NCT00860977 Phase 3 valacyclovir;Placebo
31 Impact of Episodic Acyclovir Therapy on Ulcer Duration and HIV Shedding From Genital Ulcers Among Men in South Africa Completed NCT00164424 Phase 2, Phase 3 Acyclovir
32 Effect of Safe Male Circumcision on Incidence of Infection by HIV, HSV-2 and of Genital Ulceration Terminated NCT00122525 Phase 3
33 A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults Completed NCT02030301 Phase 1, Phase 2
34 A Randomized, Double-Blind Study to Evaluate a New Formulation of GEN-003 in Subjects With Genital HSV-2 Infection Completed NCT02515175 Phase 2 Placebo
35 A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes Completed NCT00486200 Phase 2 ASP2151;valacyclovir;Placebo
36 Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 - Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Completed NCT02300142 Phase 2
37 A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection Completed NCT02114060 Phase 2
38 A Phase I/IIa, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study of the Safety and Immunogenicity of a HSV-2 Vaccine Containing Matrix M-2 Adjuvant in Individuals With Documented Genital HSV-2 Genital Infection Completed NCT01667341 Phase 1, Phase 2
39 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection Completed NCT02837575 Phase 2
40 Assessment of Local Retention and Duration of Activity of SPL7013 Following Vaginal Application of 3% SPL7013 Gel (VivaGel) in Healthy Volunteers Completed NCT00740584 Phase 1, Phase 2 3% SPL7013 Gel (VivaGel)
41 Efficacy of an HSV2 Genital Herpes Suppressive Treatment on HIV and HSV2 Genital Shedding Among Co-Infected Patients Receiving or Not Antiretroviral Drugs Completed NCT00158509 Phase 2 Valacyclovir
42 A Phase 2a Multicenter, Double-blinded, Randomized Trial to Evaluate The Effect of HerpV on Viral Shedding in Adults With Recurrent Genital Herpes Completed NCT01687595 Phase 2 HerpV and QS-21;Placebo
43 Anti-Herpetic Treatment Associated With Syndromic Management of Genital Ulcer in Africa: Clinical and Biological Evaluation on HIV-1 and HSV-2 Shedding (ANRS 1212) Completed NCT00158483 Phase 2 Acyclovir (ACV)
44 A Double-blind Randomized Placebo Controlled Dose-finding Trial to Investigate Different Doses of a New Antiviral Drug in Subjects With Genital HSV Type 2 Infection Completed NCT01047540 Phase 2 AIC316;AIC316;AIC316;AIC316;Placebo
45 A Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir Prophylaxis Versus Placebo Among HIV-1/HSV-2 Co-Infected Individuals in Uganda Completed NCT00405821 Phase 2 Acyclovir;Placebo
46 HSV-1 Suppression in HCV Infected Veterans Who Are Seronegative for HSV-2 Completed NCT01580995 Phase 2 Valacyclovir;Placebo
47 A Phase II, Randomized, Double-blind, Placebo-controlled Trial of Acyclovir for the Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load and Mucosal Shedding in HIV-1, Herpes Simplex Virus, Type 2 (HSV-2) Co-Infected Women Completed NCT00371592 Phase 2 Acyclovir;Acyclovir placebo
48 A Randomized, Double-Blind, Double-Dummy Phase II Study of Single Dose HDIT101 Versus Standard of Care Valaciclovir in Patients With Chronic Recurrent Anogenital HSV-2 Infection Recruiting NCT04165122 Phase 2 Valaciclovir;Valaciclovir placebo
49 Anti-viral Therapy in Alzheimer's Disease Recruiting NCT03282916 Phase 2 Valacyclovir;Placebo
50 A Two-Stage, Randomized, Double-Blind, Dose-Ranging, Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 on HSV Shedding in Adults With Recurrent Genital HSV-2 Infection. Not yet recruiting NCT03595995 Phase 2
51 A Phase II Open-label, Intra-individual Controlled, Single-center Study to Investigate the Efficacy, Safety and Tolerability of a Polyethylene Glycol-formulation and the Viral Shedding in Patients Suffering From Genital Herpes Terminated NCT01765114 Phase 2 PEG-Formulation
52 A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection Terminated NCT03146403 Phase 2
53 A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of "AIC316 (Pritelivir)" 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults. Terminated NCT01658826 Phase 2 AIC316;Valacyclovir
54 Human OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson's Disease Unknown status NCT02780895 Phase 1 Human Stem Cells
55 A Phase 1 Trial Evaluating Safety, Tolerability and Immune Response of AG-707 Compared to Placebo in HSV-2 Seropositive Patients Completed NCT00231049 Phase 1 AG-707
56 A Phase I, Two-Center, Open-Label, Dose-Escalating Study to Investigate the Safety, Tolerability and Immunogenicity of pPJV7630, a Therapeutic DNA Vaccine for Herpes Simplex Virus Type 2 (HSV-2), in Patients With Recurrent Genital Herpes Caused by HSV-2 Completed NCT00274300 Phase 1
57 Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection Completed NCT01915212 Phase 1
58 A Double-Blind, Placebo-Controlled Single Dose Escalating Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2151 in Healthy Male Subjects, Followed by an Open, Two-Period Crossover Study to Assess the Effect of Fed Conditions on the Safety, Tolerability and Pharmacokinetics of ASP2151 Completed NCT02852876 Phase 1 ASP2151;Placebo
59 Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and Herpes Simplex Virus 2 (HSV-2) Infection (Phase I) Completed NCT01453075 Phase 1 Valacyclovir;Placebo
60 An Expanded Phase I Randomized Placebo Controlled Trial of the Safety and Tolerability of 3 Percent w/w SPL7013 Gel (VivaGel™) in Healthy Young Women When Administered Twice Daily for 14 Days Completed NCT00331032 Phase 1 3% w/w SPL7013 Gel;Placebo
61 Safety, Efficacy, and Patient Satisfaction of Cervical Ripening With Transcervical Use of the Foley Catheter in an Outpatient Setting Unknown status NCT01605474
62 A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection Completed NCT02910284
63 A Single Center, Open Label, Longitudinal Single Arm Study to Compare the Efficacy and Safety of Prophylactic Famciclovir 500 mg b.d. in HIV Positive Adults With Recurrent Genital Herpes. Completed NCT01154543
64 Prospective Study of Pharmacokinetics, Clinical and Virologic Response to Acyclovir Episodic Therapy for Genital Herpes Ulcers in HIV Negative African Women Completed NCT02053142 Acyclovir;Placebo
65 Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis) Completed NCT01390805 Valaciclovir Hydrochloride.
66 The Effect of Treatment With Valacyclovir 500 mg BID on the Detection of HIV From Genital HSV Lesions in HIV-Infected Patients: A Double-Blind Crossover Study Completed NCT00002404 Valacyclovir hydrochloride
67 Prospective Study of Pharmacokinetics, Clinical and Virologic Response to Acyclovir Episodic Therapy for Genital Herpes Ulcers in HIV Negative African Women Completed NCT00808405 acyclovir;matching placebo
68 Half-life and Pattern of Resolution of Herpes Simplex Virus Type 2 (HSV-2) Shedding After Beginning Acyclovir Treatment Completed NCT00495573 acyclovir
69 The VIBLOK SAfety and perFormancE Trial Completed NCT03080961
70 Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2: Development of Testing Strategies Completed NCT01112956
71 HIV Prevalence, Incidence and HSV-2 Prevalence Among High-Risk MSM in Lima, Peru Completed NCT00023582
72 Persistence of Epstein-Barr Virus in Vivo Completed NCT00005924
73 A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fasting Conditions Completed NCT01132729 Valacyclovir Hydrochloride
74 A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fed Conditions Completed NCT01132716 Valacyclovir Hydrochloride
75 HSV Seroprevalence and Diagnosis of Genital Herpes in Pregnant Women Completed NCT00291044
76 A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients Completed NCT00002084 Valacyclovir hydrochloride;Acyclovir
77 A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients Completed NCT00002000 Valacyclovir hydrochloride;Acyclovir
78 Sexually Transmitted Infections Among African American Women Who Have Sex With Women Completed NCT01546714
79 Examining the Ability of HSV2 Therapy to Reduce HIV Target Cell Numbers in the Cervix. Completed NCT00946556 Valacyclovir;Placebo
80 DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women Completed NCT01874158
81 Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daiy Valacyclovir in the Reduction of HSV-2 Recurrences and Viral Shedding Completed NCT00803543 Valacyclovir;Placebo
82 Polymorphism of the Herpes Simplex Virus Receptor Completed NCT00001648
83 A Case Control Study of Women With Multiple Sexual Partners Attending the Jefferson County Department of Health Sexually Transmitted Diseases Clinic Completed NCT01578915
84 Impact Evaluation of a School-Based Sexuality and HIV Prevention Education Activity in South Africa Completed NCT04205721
85 A Randomized Controlled Trial Evaluating Efficacy of Promoting Voluntary Medical Male Circumcision Among Male Sexually Transmitted Diseases Patients in China Completed NCT03414710
86 Comparative Effectiveness of Treatment Options for Genital Herpes Infection in Pregnant Women to Reduce Adverse Pregnancy Outcomes Active, not recruiting NCT02986802
87 Safety and Efficacy of Er:YAG and Nd:YAG Laser Therapy in Gynecology: A Retrospective Case Series. Active, not recruiting NCT04073082
88 Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA) Active, not recruiting NCT03092505
89 Evaluation of Different Methods for Rapid Diagnosis of Meningitis in Assiut University Hospital Not yet recruiting NCT03759470
90 An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons Withdrawn NCT01059084 Valacyclovir

Search NIH Clinical Center for Genital Herpes

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acyclovir
Acyclovir Sodium
famciclovir
Foscarnet
Foscarnet Sodium Hexahydrate
Interferon Alfa-2b
valacyclovir
Valacyclovir hydrochloride

Cochrane evidence based reviews: herpes genitalis

Genetic Tests for Genital Herpes

Anatomical Context for Genital Herpes

The Foundational Model of Anatomy Ontology organs/tissues related to Genital Herpes:

19
Genital System, Rectum

MalaCards organs/tissues related to Genital Herpes:

40
Testes, T Cells, Skin, Cervix, Lymph Node, Lung, B Cells

Publications for Genital Herpes

Articles related to Genital Herpes:

(showing 3224, show less)
# Title Authors PMID Year
1
Increasing proportion of herpes simplex virus type 1 among women and men diagnosed with first-episode anogenital herpes: a retrospective observational study over 14 years in Melbourne, Australia. 42
30554143 2019
2
Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions. 42
30853029 2019
3
Herpes Simplex Virus Type 2 Infection-Induced Expression of CXCR3 Ligands Promotes CD4+ T Cell Migration and Is Regulated by the Viral Immediate-Early Protein ICP4. 42
30619292 2018
4
Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. 54 61
19702506 2009
5
Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. 54 61
7911177 1994
6
Passive immunization of the vagina protects mice against vaginal transmission of genital herpes infections. 54 61
8158042 1994
7
Antiviral effect of Chinese herbal prescription JieZe-1 on adhesion and penetration of VK2/E6E7 with herpes simplex viruses type 2. 61
31743766 2020
8
Effects of CD4 cell count and antiretroviral therapy on mucocutaneous manifestations among HIV/AIDS patients in Yunnan, China. 61
31846069 2020
9
Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial. 61
32034019 2020
10
Peculiar vegetative tumor-like genital herpes simplex nodules with brisk tissue eosinophilia in patients with human immunodeficiency virus infection. 61
31437312 2020
11
Genital herpes zoster in an immunocompetent child. 61
32031528 2020
12
Genital zoster in near term pregnancy: Case report and need of management guidelines. 61
31852623 2020
13
Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology. 61
31617171 2020
14
Aberrant cervical innate immunity predicts onset of dysbiosis and sexually transmitted infections in women of reproductive age. 61
31914129 2020
15
Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis. 61
32027675 2020
16
An unusual presentation of genital herpes in a patient affected by lichen sclerosus et atrophicus: A case report and a combined treatment proposal. 61
31997518 2020
17
[Anal herpes simplex virus infections]. 61
31965208 2020
18
Estimating nationwide cases of sexually transmitted diseases in 2015 from sentinel surveillance data in Japan. 61
31992256 2020
19
Time Trends in First-Episode Genital Herpes Simplex Virus Infections in an Urban Sexually Transmitted Disease Clinic. 61
31764767 2019
20
Oral Transmission of Sexually Transmissable Infections: A Narrative Review. 61
31851887 2019
21
Genital Infection With Herpes Simplex Virus Type 1 and Type 2 in Valencia, Spain: A Retrospective Observational Study. 61
31744595 2019
22
Depot-medroxyprogesterone acetate reduces genital cell-cell adhesion molecule expression and increases genital herpes simplex virus type 2 infection susceptibility in a dose-dependent fashion. 61
31302121 2019
23
Herpetiform aphthous genital ulcers misdiagnosed as herpes genitalis in a young male and their effective response to colchicine therapy. 61
31775589 2019
24
[Acute genital ulcers in a young woman]. 61
31769629 2019
25
Maintaining Breastfeeding During Severe Infant and Maternal HSV-1 Infection: A Case Report. 61
30840531 2019
26
Association of HIV-syphilis coinfection with optimal antiretroviral adherence: a nation-wide claims study. 61
31690082 2019
27
Granzyme B Cleaves Multiple Herpes Simplex Virus 1 and Varicella-Zoster Virus (VZV) Gene Products, and VZV ORF4 Inhibits Natural Killer Cell Cytotoxicity. 61
31462576 2019
28
Data-driven queries between medications and spontaneous preterm birth among 2.5 million pregnancies. 61
31433567 2019
29
Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes. 61
31515143 2019
30
Time Trends in First Episode Genital Herpes Simplex Virus Infections in an Urban STD Clinic. 61
31688723 2019
31
Herpes simplex virus type 1 epidemiology in Africa: Systematic review, meta-analyses, and meta-regressions. 61
31376458 2019
32
Recurrent herpes labialis and Herpes simplex virus-1 genitalis: what is the link? 61
28181784 2019
33
Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV. 61
31645394 2019
34
Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. 61
31541030 2019
35
A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection. 61
31058977 2019
36
Drug-encapsulated carbon (DECON): A novel platform for enhanced drug delivery. 61
31453334 2019
37
Contriving a chimeric polyvalent vaccine to prevent infections caused by herpes simplex virus (type-1 and type-2): an exploratory immunoinformatic approach. 61
31328668 2019
38
Migrant memory B cells secrete luminal antibody in the vagina. 61
31189952 2019
39
A Case of Dermatitis Herpetiformis With Fibrillar Immunoglobulin A Deposition: A Rare Pattern Not to Be Missed. 61
30839342 2019
40
Sacral Myeloradiculitis: An Uncommon Complication of Genital Herpes Infection. 61
31217310 2019
41
Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants. 61
31153687 2019
42
Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease. 61
31103365 2019
43
Atypical Presentation of Herpes Simplex Virus Type 2 Infection Refractory to Treatment With Aciclovir in 2 Hematologic Patients. 61
29203034 2019
44
Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4+ and CD8+ TRM Cells Associated with Protection against Recurrent Genital Herpes. 61
30787156 2019
45
18F-FDG PET/CT Findings in Disseminated Genital Herpes in an Immunocompetent Patient With Anaplastic Lymphoma Kinase Rearranged Advanced Nonsmall Cell Lung Cancer. 61
30829864 2019
46
Sexually Transmitted Diseases in the Emergency Department. 61
30940365 2019
47
[Cutaneous Herpesvirus Infection]. 61
30988211 2019
48
Genital ulcers caused by herpes simplex virus. 61
30580877 2019
49
Vegetative chronic genital herpes with satisfactory response to imiquimod. 61
31090830 2019
50
Herpes Simplex Infection During Pregnancy, Results of a Tertiary Referral Center in Turkey. 61
30831604 2019
51
Sexually transmitted infections, active component, U.S. Armed Forces, 2010-2018. 61
30912663 2019
52
A merged molecular docking, ADME-T and dynamics approaches towards the genus of Arisaema as herpes simplex virus type 1 and type 2 inhibitors. 61
30579134 2019
53
The Epidemiology of Herpes Simplex Virus Type 1 in Asia: Systematic Review, Meta-analyses, and Meta-regressions. 61
30020453 2019
54
Expression of Concern to: Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. 61
30725243 2019
55
Signs heralding appearance of thymomas after extended thymectomy for myasthenia gravis. 61
30859007 2019
56
Antiviral Properties of R. tanguticum Nanoparticles on Herpes Simplex Virus Type I In Vitro and In Vivo. 61
31555137 2019
57
The Effect of Hormonal Contraception and Menstrual Cycle Timing on Genital Herpes Simplex Virus-2 Shedding and Lesions. 61
30148758 2019
58
Herpes simplex virus type 1 epidemiology in Latin America and the Caribbean: Systematic review and meta-analytics. 61
31009486 2019
59
A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection. 61
30551986 2019
60
Behavioral, Psychological, Gender, and Health Service Correlates to Herpes Simplex Virus Type 2 Infection among Young Adult Mexican-American Women Living in a Disadvantaged Community. 61
29558260 2019
61
Herpes Simplex Virus Type 2 Immediate Early Protein ICP27 Inhibits IFN-β Production in Mucosal Epithelial Cells by Antagonizing IRF3 Activation. 61
30863402 2019
62
In vitro and in vivo anti-herpes simplex virus activity of monogalactosyl diacylglyceride from Coccomyxa sp. KJ (IPOD FERM BP-22254), a green microalga. 61
31310628 2019
63
Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial. 61
31846475 2019
64
[Diagnostic and therapeutic recommendations for sexually transmitted diseases: Genital herpes]. 61
30366717 2019
65
The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes. 61
30471955 2019
66
Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials. 61
30917165 2019
67
Extensive vulval and perianal ulceration due to genital herpes virus infection. 61
31143869 2019
68
Hampering Herpesviruses HHV-1 and HHV-2 Infection by Extract of Ginkgo biloba (EGb) and Its Phytochemical Constituents. 61
31681227 2019
69
HSV-2 Cellular Programming Enables Productive HIV Infection in Dendritic Cells. 61
31867020 2019
70
The Effect of Aloe Vera Clinical Trials on Prevention and Healing of Skin Wound: A Systematic Review. 61
30666070 2019
71
Association of abnormal cervical cytology with coinfection of human papillomavirus and Chlamydia trachomatis. 61
31143862 2019
72
Herpes Simplex Virus Type 2 Radiculomyelitis Disguised as Conversion Disorder. 61
31543792 2019
73
Immuno-metabolic changes in herpes virus infection. 61
29960669 2018
74
Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition. 61
29175899 2018
75
Comparison of Acyclovir and Multistrain Lactobacillus brevis in Women with Recurrent Genital Herpes Infections: a Double-Blind, Randomized, Controlled Study. 61
28852985 2018
76
Genital Herpes Zoster as Possible Indicator of HIV Infection. 61
30665486 2018
77
Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons. 61
30289810 2018
78
Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial. 61
29982727 2018
79
Herpes Simplex Virus 1 and 2 in Herpes Genitalis: A Polymerase Chain Reaction-Based Study from Kerala. 61
30504975 2018
80
Disease Pattern among Sexually Transmitted Infection Clinic Attendees: A Hospital-Based Study. 61
30504980 2018
81
Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals. 61
30020484 2018
82
Evaluation of an Integrated Cell Culture-based and PCR Assay for Diagnosis of Genital Herpes in Women. 61
30390721 2018
83
Longitudinal association of gonorrhea and bacterial vaginosis with repeat chlamydia diagnoses among U.S. Army women: a retrospective cohort analysis. 61
30373657 2018
84
ACOG Committee Opinion No. 754 Summary: The Utility of and Indications for Routine Pelvic Examination. 61
30247359 2018
85
ACOG Committee Opinion No. 754: The Utility of and Indications for Routine Pelvic Examination. 61
30247363 2018
86
Interferon epsilon in the reproductive tract of healthy and genital herpes simplex virus-infected pregnant women: Results of a pilot study. 61
29905034 2018
87
Antiviral Activity of Tannic Acid Modified Silver Nanoparticles: Potential to Activate Immune Response in Herpes Genitalis. 61
30261662 2018
88
Surgical excision of a large, verrucous, scrotal mass in a patient with HSV-2 and HIV-1 co-infection. 61
29988734 2018
89
Should Caesarian Section Be Offered to Women With Recurrent Genital Herpes Simplex Lesions After >4 Hours of Ruptured Membranes? 61
30103879 2018
90
In Vivo Knockdown of the Herpes Simplex Virus 1 Latency-Associated Transcript Reduces Reactivation from Latency. 61
29875240 2018
91
Addressing the Increased Incidence of Common Sexually Transmitted Infections. 61
30073343 2018
92
Women infected with HIV and the impact of associated sexually transmitted infections. 61
29656416 2018
93
Update on Neonatal Herpes Simplex Epidemiology in the Netherlands: A Health Problem of Increasing Concern? 61
29356762 2018
94
Cost of Routine Herpes Simplex Virus Infection Visits to U.S. Emergency Departments 2006-2013. 61
30013705 2018
95
Genome-Wide Surveillance of Genital Herpes Simplex Virus Type 1 From Multiple Anatomic Sites Over Time. 61
29920588 2018
96
Quality of life and depression in chronic sexually transmitted infections in UK and Greece: The use of WHOQOL-HIV/STI BREF. 61
30605425 2018
97
Viral Hypothesis and Antiviral Treatment in Alzheimer's Disease. 61
30008124 2018
98
Antiviral Effect of Retro-2.1 against Herpes Simplex Virus Type 2 In Vitro. 61
29847864 2018
99
Transcriptional Analysis of the Guinea Pig Mucosal Immune Response to Intravaginal Infection with Herpes Simplex Virus Type 2. 61
29604476 2018
100
Prevention and management of genital herpes simplex infection during pregnancy and delivery: Guidelines from the French College of Gynaecologists and Obstetricians (CNGOF). 61
29571124 2018
101
[Genital herpes]. 61
29798750 2018
102
Health-related quality of life of young people and adults with primary or recurrent episodes of genital herpes: a mixed methods systematic review protocol. 61
29762300 2018
103
Proteflazid®: treatment of herpesvirus and mixed infections. Meta-analysis of clinical trials results. 61
29813042 2018
104
Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8+ TEM and TRM Cell Responses against Herpesvirus Infection and Disease. 61
29437976 2018
105
CXCL17 Chemokine-Dependent Mobilization of CXCR8+CD8+ Effector Memory and Tissue-Resident Memory T Cells in the Vaginal Mucosa Is Associated with Protection against Genital Herpes. 61
29549178 2018
106
STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice. 61
29608601 2018
107
Co-infection of human herpesvirus type 2 (HHV-2) and human immunodeficiency virus (HIV) among pregnant women in Rio de Janeiro, Brazil. 61
28914079 2018
108
Self-reported minor infections in patients with hidradenitis suppurativa and healthy controls. 61
28994129 2018
109
A case of hypertrophic herpes simplex virus affecting the eyelid and cornea masquerading as IgG4-related disease. 61
29468223 2018
110
Antiviral Effects of ABMA against Herpes Simplex Virus Type 2 In Vitro and In Vivo. 61
29522484 2018
111
Genital herpes stigma: Toward the Measurement and Validation of a highly prevalent yet hidden public health problem. 61
29629409 2018
112
The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase. 61
29186456 2018
113
Anti HSV-2 activity of Peganum harmala (L.) and isolation of the active compound. 61
29223449 2018
114
The Ticking CLOCK of HSV-2 Pathology. 61
29273146 2018
115
Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains. 61
29069622 2018
116
[Erratum to "Management of pregnant women with first episode of genital herpes. Guidelines for clinical practice from the French college of gynecologists and obstetricians (CNGOF)" [Gynecol Obstet Fertil Senol. 45 (2017) 664-76]]. 61
29274775 2018
117
Hyperosmolal vaginal lubricants markedly reduce epithelial barrier properties in a three-dimensional vaginal epithelium model. 61
29854584 2018
118
Clinical Trial of Herbal Treatment Gene-Eden-VIR/Novirin in Oral Herpes. 61
30362389 2018
119
A Case-Control Study in Primary Care Settings on the Roles of Dermatoscopy in Infectious Diseases Affecting the Skin, Part 1: Viral and Bacterial Infections. 61
30207527 2018
120
The first case of lymphogranuloma venereum in a woman in East-Central Europe and its multiple co-infections. 61
28741042 2018
121
The Etiology of Genital Ulcer Disease and Coinfections With Chlamydia trachomatis and Neisseria gonorrhoeae in Zimbabwe: Results From the Zimbabwe STI Etiology Study. 61
29240636 2018
122
The Role of Polymorphonuclear Leukocyte Counts from Urethra, Cervix, and Vaginal Wet Mount in Diagnosis of Nongonococcal Lower Genital Tract Infection. 61
30147292 2018
123
[Clinical, epidemiological, and etiological studies of adult aseptic meningitis: a report of 12 cases of herpes simplex meningitis, and a comparison with cases of herpes simplex encephalitis]. 61
29269697 2018
124
Antiviral Drugs Against Alphaherpesvirus. 61
29896665 2018
125
Exogenous oestrogen inhibits genital transmission of cell-associated HIV-1 in DMPA-treated humanized mice. 61
29334191 2018
126
CONCOMITANT SEXUALLY TRANSMITTED DISEASES IN PATIENTS WITH DIAGNOSED HIV/AIDS: A RETROSPECTIVE STUDY. 61
29619436 2018
127
Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study. 61
29281620 2017
128
2017 European guidelines for the management of genital herpes. 61
28836892 2017
129
Clinacanthus nutans: a review on ethnomedicinal uses, chemical constituents and pharmacological properties. 61
28198202 2017
130
[Management of pregnant women with recurrent herpes. Guidelines for clinical practice from the French College of Gynecologists, Obstetricians (CNGOF)]. 61
29132770 2017
131
[Management of pregnant women with first episode of genital herpes. Guidelines for clinical practice from the French college of gynecologists and obstetricians (CNGOF)]. 61
29132767 2017
132
[Genital herpes and pregnancy: Serological and molecular diagnostic tools. Guidelines for clinical practice from the French College of Gynecologists and Obstetricians (CNGOF)]. 61
29132769 2017
133
The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II. 61
28197698 2017
134
Primary syphilis in pregnancy mistaken for genital herpes: A preventable cause of congenital syphilis. 61
29103618 2017
135
A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model. 61
28481687 2017
136
Media Consumption and Creation in Attitudes Toward and Knowledge of Inflammatory Bowel Disease: Web-Based Survey. 61
29222081 2017
137
[Genital herpes and pregnancy: Epidemiology, clinical manifestations, prevention and screening. Guidelines for clinical practice from the French College of Gynecologists and Obstetrician (CNGOF)]. 61
29146286 2017
138
[Neonatal herpes: Epidemiology, clinical manifestations and management. Guidelines for clinical practice from the French College of Gynecologists and Obstetricians (CNGOF)]. 61
29132771 2017
139
Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate. 61
28914197 2017
140
Pregnancy Outcomes in Association with STDs including genital HSV-2 shedding in a South African Cohort Study. 61
28396556 2017
141
Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster. 61
29451274 2017
142
A high resolution melting (HRM) technology-based assay for cost-efficient clinical detection and genotyping of herpes simplex virus (HSV)-1 and HSV-2. 61
28734843 2017
143
Cutting Edge: Genetic Association between IFI16 Single Nucleotide Polymorphisms and Resistance to Genital Herpes Correlates with IFI16 Expression Levels and HSV-2-Induced IFN-β Expression. 61
28893956 2017
144
A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection. 61
29055448 2017
145
Sexually transmitted infection prevalence and related risk factors among heterosexual male methamphetamine users in China. 61
28178893 2017
146
Skin diseases of the vulva: Infectious diseases. 61
28397528 2017
147
Genital herpes. 61
28619732 2017
148
Differential expression of mRNA and miRNA in guinea pigs following infection with HSV2v. 61
28962197 2017
149
Genital Herpes Infection in an Adolescent with Diabetes Mellitus. 61
28891491 2017
150
Skin diseases of the male external genitalia in the Tanlangai Hospital in Brazzaville, Congo. 61
28947407 2017
151
A model of genital herpes simplex virus Type 1 infection in Rhesus Macaques. 61
28748667 2017
152
No. 208-Guidelines for the Management of Herpes Simplex Virus in Pregnancy. 61
28729112 2017
153
No. 207-Genital Herpes: Gynaecological Aspects. 61
28625289 2017
154
Prevalence of herpes simplex virus types 1 and 2 at maternal and fetal sides of the placenta in asymptomatic pregnant women. 61
28440579 2017
155
Herpes simplex virus: 'to disclose or not to disclose.' An exploration of the multi-disciplinary team's role in advising patients about disclosure when diagnosed with genital herpes simplex virus. 61
27582307 2017
156
A retrospective study of the pattern of sexually transmitted infections from a tertiary care hospital of Rajasthan. 61
30148268 2017
157
Potential risk of developing herpes simplex encephalitis in patients treated with sildenafil following primary exposure to genital herpes. 61
28956417 2017
158
Correlating CD4 count with mucocutaneous manifestations in HIV-positive patients: A prospective study. 61
30148265 2017
159
Lifetime Sexual Assault and Sexually Transmitted Infections Among Women Veterans. 61
28281918 2017
160
Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging. 61
28614387 2017
161
Serologic Screening for Genital Herpes Infection. 61
28671417 2017
162
Serologic Screening for Genital Herpes Infection: Recommendation Statement. 61
28671418 2017
163
Recalcitrant hypertrophic herpes genitalis in HIV-infected patient successfully treated with topical imiquimod. 61
28261899 2017
164
The Product of the Herpes Simplex Virus 2 UL16 Gene Is Critical for the Egress of Capsids from the Nuclei of Infected Cells. 61
28275195 2017
165
Herpes simplex virus specific T cell response in a cohort with primary genital infection correlates inversely with frequency of subsequent recurrences. 61
27903680 2017
166
NK cells require antigen-specific memory CD4+ T cells to mediate superior effector functions during HSV-2 recall responses in vitro. 61
27974365 2017
167
Dorsal longitudinal foreskin cut is associated with reduced risk of HIV, syphilis and genital herpes in men: a cross-sectional study in Papua New Guinea. 61
28406272 2017
168
Extensive and refractory genital herpes in human immunodeficiency virus-infected patient successfully treated with imiquimod: Case report and literature review. 61
28164895 2017
169
Screening for Genital Herpes: What Is Not to Be Done. 61
27997634 2017
170
Periodic Screening Pelvic Examination: Evidence Report and Systematic Review for the US Preventive Services Task Force. 61
28267861 2017
171
PARTNER NOTIFICATION OUTCOMES AMONG MALE GONORRHEA PATIENTS AT BANGRAK HOSPITAL, BANGKOK, THAILAND. 61
29642299 2017
172
Sexual health of women aged 40 and over attending an inner city integrated sexual health clinic. 61
28198339 2017
173
Proteflazid® and local immunity in diseases caused by human papillomavirus, herpesvirus and mixed urogenital infections. 61
28333902 2017
174
[The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II. German version]. 61
28197699 2017
175
Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial. 61
28329211 2017
176
Epidemiological aspects of genital ulcers at the STI center of the National Institute of Public Hygiene (Abidjan, Côte d'Ivoire) 2008 to 2010. 61
28406423 2017
177
The Characteristics of Herpes Simplex Virus Type 1 Infection in Rhesus Macaques and the Associated Pathological Features. 61
28146109 2017
178
First-episode genital herpes: interventions for men and women. 61
28120659 2017
179
A Comparative Analysis of Polymerase Chain Reaction and Direct Fluorescent Antibody Test for Diagnosis of Genital Herpes. 61
28042218 2017
180
Mechanistic Studies of Viral Entry: An Overview of Dendrimer-Based Microbicides As Entry Inhibitors Against Both HIV and HSV-2 Overlapped Infections. 61
27518199 2017
181
An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs. 61
28103319 2017
182
Leflunomide in the Treatment of a Pseudotumoral Genital Herpes Simplex Virus Infection in an HIV Patient. 61
28373917 2017
183
Herpes simplex virus 1 and 2 educational assessment of young adults in rural southwest Virginia. 61
28654651 2017
184
Invasive Obstetric Procedures and Cesarean Sections in Women With Known Herpes Simplex Virus Status During Pregnancy. 61
29308404 2017
185
External Use of Propolis for Oral, Skin, and Genital Diseases: A Systematic Review and Meta-Analysis. 61
28265293 2017
186
Antiviral Medication in Sexually Transmitted Diseases. Part III: Hepatitis B, Hepatitis C. 61
27515715 2017
187
Sexual Lifestyle, Risk Factors and Socioeconomic Status of the STD Patients in Bangladesh. 61
28260751 2017
188
Development of Recombinant HSV-Based Vaccine Vectors. 61
28374243 2017
189
Clinico-epidemiological profile of patients attending Suraksha Clinic of tertiary care hospital of North India. 61
28442804 2017
190
[Endometrial dysfunction caused by chronic endometritis: сlinical and morphological aspects]. 61
29265074 2017
191
Herpes Genitalis: Diagnosis, Treatment and Prevention. 61
28017972 2016
192
JAMA patient page: Screening for Genital Herpes. 61
27997655 2016
193
HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions. 61
27853144 2016
194
Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. 61
27997660 2016
195
Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. 61
27766602 2016
196
A Recommendation Against Serologic Screening for Genital Herpes Infection-What Now? 61
27997636 2016
197
Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Recommendation Statement. 61
27997659 2016
198
Tuberculosis of Glans Penis- A Rare Presentation. 61
28208927 2016
199
Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells. 61
27407095 2016
200
Sexual temptation: substance abuse, no sex, safe sex, risky sex, and STDs. 61
28009539 2016
201
Genital Herpes. 61
27959656 2016
202
Genital Herpes. 61
27959657 2016
203
[Genital herpes]. 61
27771124 2016
204
Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection. 61
27007679 2016
205
Characterization of Vesicular Stomatitis Virus Pseudotypes Bearing Essential Entry Glycoproteins gB, gD, gH, and gL of Herpes Simplex Virus 1. 61
27605677 2016
206
Examining the role of socioeconomic deprivation in ethnic differences in sexually transmitted infection diagnosis rates in England: evidence from surveillance data. 61
27511704 2016
207
[Interferon in combined therapy of human papillomavirus infections associated with sexually transmitted infections. linical observation]. 61
28248030 2016
208
Herpes simplex virus type 2-associated recurrent aseptic meningitis (Mollaret's meningitis) with a recurrence after 11-year interval: a case report. 61
27773908 2016
209
Associations between individual and relationship characteristics and genital herpes disclosure. 61
25814164 2016
210
Two cases of genital neutrophilic sebaceous adenitis. 61
27178726 2016
211
Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes. 61
27351137 2016
212
Prevalence and associated factors of behavioral intention for risk compensation following voluntary medical male circumcision among male sexually transmitted diseases patients in China. 61
27120407 2016
213
Cesarean Delivery in Adolescents. 61
26836505 2016
214
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. 61
27733282 2016
215
Association of Depressed Mood With Herpes Simplex Virus-2 Immunoglobulin-G Levels in Pregnancy. 61
27490851 2016
216
HSV-2 glycoprotein gD targets the CC domain of tetherin and promotes tetherin degradation via lysosomal pathway. 61
27630089 2016
217
Attitudes and Willingness to Assume Risk of Experimental Therapy to Eradicate Genital Herpes Simplex Virus Infection. 61
27513383 2016
218
Metastastic vulvar squamous cell carcinoma mimicking genital herpes. 61
27752532 2016
219
Sexually Transmitted Infections Among Hospitalized Patients With Human Immunodeficiency Virus Infection and Acquired Immune Deficiency Syndrome (HIV/AIDS) in Zahedan, Southeastern Iran. 61
27818966 2016
220
Sexually transmitted infections and HIV in self reporting men who have sex with men: A two-year study from India. 61
26776704 2016
221
Secreted herpes simplex virus-2 glycoprotein G alters thermal pain sensitivity by modifying NGF effects on TRPV1. 61
27576911 2016
222
Herpes simplex virus type 1 and type 2 in the Netherlands: seroprevalence, risk factors and changes during a 12-year period. 61
27484304 2016
223
Genital herpes. 61
27109044 2016
224
CLINICAL PRACTICE. Genital Herpes. 61
27532832 2016
225
Integrative pharmacokinetic-pharmacodynamic modeling and simulation of amenamevir (ASP2151) for treatment of recurrent genital herpes. 61
27461507 2016
226
Sexually transmitted infections case notification rates in the Kingdom of Saudi Arabia, 2005-2012. 61
27580336 2016
227
Functional prediction of differentially expressed lncRNAs in HSV-1 infected human foreskin fibroblasts. 61
27496175 2016
228
Interventions for men and women with their first episode of genital herpes. 61
27575957 2016
229
Role of type-specific herpes simplex virus-1 and 2 serology as a diagnostic modality in patients with clinically suspected genital herpes: A comparative study in Indian population from a tertiary care hospital. 61
27510668 2016
230
In Situ Detection of Regulatory T Cells in Human Genital Herpes Simplex Virus Type 2 (HSV-2) Reactivation and Their Influence on Spontaneous HSV-2 Reactivation. 61
27117511 2016
231
Collaboration with a midwife in the care of a pregnant patient with recurrent genital herpes simplex virus. 61
27412208 2016
232
Subclinical generation of acyclovir-resistant herpes simplex virus with mutation of homopolymeric guanosine strings during acyclovir therapy. 61
26917345 2016
233
HSV antivirals - current and future treatment options. 61
26897058 2016
234
False-negative type-specific glycoprotein G antibody responses in STI clinic patients with recurrent HSV-1 or HSV-2 DNA positive genital herpes, The Netherlands. 61
26755775 2016
235
Genital Herpes: A Review. 61
27281837 2016
236
Genital Herpes: What You Should Know. 61
27281843 2016
237
Genital Herpes: Insights into Sexually Transmitted Infectious Disease. 61
28357380 2016
238
Intravaginal Zinc Oxide Tetrapod Nanoparticles as Novel Immunoprotective Agents against Genital Herpes. 61
27183601 2016
239
CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. 61
27362483 2016
240
Viral Spread to Enteric Neurons Links Genital HSV-1 Infection to Toxic Megacolon and Lethality. 61
27281569 2016
241
First HSV-1 non primary genital herpes in two patients. 61
27018573 2016
242
Access of protective antiviral antibody to neuronal tissues requires CD4 T-cell help. 61
27225131 2016
243
[Construction and Immunogenicity Analysis of Herpes Simplex Virus Type 2 Glycoprotein D Recombinant Adenovirus Vaccine]. 61
29962197 2016
244
Evolution of rational vaccine designs for genital herpes immunotherapy. 61
26896782 2016
245
Effects of a traditional Chinese medicine, Longdanxiegan formula granule, on Toll-like receptor pathway in female guinea pigs with recurrent genital herpes. 61
27125405 2016
246
Coping strategies and behavioural changes following a genital herpes diagnosis among an urban sample of underserved Midwestern women. 61
25792549 2016
247
Seroprevalence and risk factors of herpes simplex virus-2 among pregnant women attending antenatal care at health facilities in Wolaita zone, Ethiopia. 61
26979484 2016
248
Does suppressive antiviral therapy for herpes simplex virus prevent transmission in an HIV-positive population? A systematic review. 61
29770002 2016
249
Unfortunate synergy between HIV and genital herpes. 61
26884529 2016
250
Stunting at 5 Years Among SGA Newborns. 61
26772663 2016
251
Predictors of the Sexual Well-being of Individuals Diagnosed with Herpes and Human Papillomavirus. 61
25408498 2016
252
Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda. 61
26486633 2016
253
Sexually transmitted infections in U.S. Air Force recruits in basic military training. 61
26930147 2016
254
Polish consensus guidelines on the use of acyclovir in the treatment and prevention of VZV and HSV infections. 61
26643900 2016
255
The Basic Domain of Herpes Simplex Virus 1 pUS9 Recruits Kinesin-1 To Facilitate Egress from Neurons. 61
26656703 2016
256
Potential impact of the human papillomavirus vaccine on the incidence proportion of genital warts in French women (EFFICAE study): a multicentric prospective observational study. 61
26567557 2016
257
Optimal management of genital herpes: current perspectives. 61
27358569 2016
258
A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2. 61
26559846 2016
259
Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus. 61
26609935 2016
260
OASL1 deficiency promotes antiviral protection against genital herpes simplex virus type 2 infection by enhancing type I interferon production. 61
26750802 2016
261
Herpes Simplex Virus 1 Infection of Tree Shrews Differs from That of Mice in the Severity of Acute Infection and Viral Transcription in the Peripheral Nervous System. 61
26512084 2016
262
The occurrence of herpes simplex viruses 1 and 2 in skin and mucosal lesions in patients with suspicion of genital herpes. 61
28146623 2016
263
Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs. 61
28082979 2016
264
Non-healing genital herpes mimicking donovanosis in an immunocompetent man. 61
25614521 2016
265
Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir. 61
27621592 2016
266
Herpes Simplex Virus-2 Esophagitis in a Young Immunocompetent Adult. 61
27195158 2016
267
Self-reported sexually transmitted infections among female university students. 61
26489857 2016
268
Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. 61
26561565 2016
269
Herpes simplex virus seroprevalence and seroconversion among active duty US air force members with HIV infection. 61
26615389 2016
270
Characteristics of Sexually Transmitted Infections among High-Risk HIV-Positive Patients Attending an Urban Clinic in Uganda. 61
24144639 2016
271
First description of herpes simplex virus type 1 epididymo-orchitis: A new clinical form of herpes simplex virus infection during septic shock? 61
27672563 2016
272
A Retrospective Study of the Pattern of Sexually Transmitted Infections in Males: Viral Infections in Emerging Trend. 61
26894160 2016
273
Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial. 61
26044291 2015
274
Updating the management of sexually transmitted infections. 61
26843713 2015
275
Successful treatment of hypertrophic herpes simplex genitalis in HIV-infected patient with topical imiquimod. 61
26074211 2015
276
High Rate of β-Globin DNA Detection Validates Self-Sampling in Herpes Simplex Virus Shedding Studies. 61
26562701 2015
277
Expression and characterization of the gD protein of HSV-2 fused to the tetramerization domain of the transcription factor p53. 61
26209556 2015
278
Patient Preferences for Test Result Notification. 61
25944020 2015
279
Valaciclovir versus aciclovir for the treatment of primary genital herpes simplex: a cost analysis. 61
25505043 2015
280
Harmine blocks herpes simplex virus infection through downregulating cellular NF-κB and MAPK pathways induced by oxidative stress. 61
26348003 2015
281
Intravenous Foscarnet With Topical Cidofovir for Chronic Refractory Genital Herpes in a Patient With AIDS. 61
26788527 2015
282
Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model. 61
26178984 2015
283
[Contribution of Electronic Health Record in Surveillance of Notifiable Diseases]. 61
26650475 2015
284
Erratum to: Diagnosis of genital herpes simplex virus infection in the clinical laboratory. 61
26463442 2015
285
The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment. 61
26157126 2015
286
Variability of human immunodeficiency virus-1 in the female genital reservoir during genital reactivation of herpes simplex virus type 2. 61
26003280 2015
287
Contribution of N-linked glycans on HSV-2 gB to cell-cell fusion and viral entry. 61
25965797 2015
288
Chitosan and Kappa-Carrageenan Vaginal Acyclovir Formulations for Prevention of Genital Herpes. In Vitro and Ex Vivo Evaluation. 61
26393621 2015
289
Seroprevalence of Herpes Simplex Virus Type 1 and Type 2 and Coinfection With HIV and Syphilis: The First National Seroprevalence Survey in Saudi Arabia. 61
26267880 2015
290
Sexually Transmitted Diseases as a Risk for Acquiring HIV Infection among the Population of Men Who Have Sex with Men--A Case-Control Study. 61
26898074 2015
291
The Contribution of Cervicovaginal Infections to the Immunomodulatory Effects of Hormonal Contraception. 61
26330510 2015
292
A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens. 61
26041292 2015
293
An age-structured model for the coupled dynamics of HIV and HSV-2. 61
25974346 2015
294
Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. 61
26018166 2015
295
A model for the coupled disease dynamics of HIV and HSV-2 with mixing among and between genders. 61
25953482 2015
296
Syphilis: Is it making resurgence? 61
26692612 2015
297
[VIRAL INFECTIONS: HUMAN PAPILLOMAVIRUS AND GENITAL HERPES TYPE 1 AND TYPE 2 AS A CAUSE OF CHRONIC RECURRENT CYSTITIS WITH SEVERE DYSURIA IN WOMEN WITH URETHRAL HYPERMOBILITY AND HYPOSPADIAS]. 61
26665761 2015
298
Study of patterns of sexually transmitted diseases using a syndromic approach in the era of human immunodeficiency virus from a tertiary care hospital of the Northern India. 61
26692608 2015
299
[TREATMENT OF PATIENTS WITH CHRONIC RECURRENT HERPES VIRUS INFECTION OF GENITAL LOCALIZATION: A CLINICAL STUDY OF FORTEPREN PREPARATION]. 61
26470430 2015
300
Production of a fragment of glycoprotein G of herpes simplex virus type 2 and evaluation of its diagnostic potential. 61
25532518 2015
301
Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. 61
25819042 2015
302
Atypical presentations of genital herpes simplex virus in HIV-1 and HIV-2 effectively treated by imiquimod. 61
24912536 2015
303
Herpes simplex virus type 2-infected dendritic cells produce TNF-α, which enhances CCR5 expression and stimulates HIV production from adjacent infected cells. 61
25840914 2015
304
Neonatal herpes infections in The Netherlands in the period 2006-2011. 61
25014318 2015
305
Young people's comparative recognition and recall of an Australian Government Sexual Health Campaign. 61
25006041 2015
306
Socio-demographic and behavioural characteristics associated with HSV-2 sero-prevalence in high risk women in KwaZulu-Natal. 61
25940115 2015
307
Molecular diagnostics and newborns at risk for genital herpes simplex virus. 61
25996200 2015
308
Novel rat models to study primary genital herpes simplex virus-2 infection. 61
25701211 2015
309
Genital herpes: oral antiviral treatments. 61
25853497 2015
310
HSV-2 immediate-early protein US1 inhibits IFN-β production by suppressing association of IRF-3 with IFN-β promoter. 61
25712217 2015
311
Relay of herpes simplex virus between Langerhans cells and dermal dendritic cells in human skin. 61
25875649 2015
312
Clinical inquiry: How well do antivirals shorten genital herpes pain duration? 61
25789347 2015
313
Neonatal herpes simplex virus infection: epidemiology and treatment. 61
25677996 2015
314
Sexually transmitted diseases. 61
25565081 2015
315
Sexually transmitted infection trends among gay or bisexual men from a clinic-based sentinel surveillance system in British Columbia, Canada. 61
25668648 2015
316
A 51-year-old man with seizures and progressive behavioral changes. 61
25732477 2015
317
Efficacy of N-methanocarbathymidine against genital herpes simplex virus type 2 shedding and infection in guinea pigs. 61
26149263 2015
318
ACP Journal Club: review: oral antiviral drugs reduce clinical recurrence in recurrent genital herpes. 61
25686194 2015
319
Seroprevalence of Herpes Simplex Virus Infection in HIV Coinfected Individuals in Eastern India with Risk Factor Analysis. 61
26557849 2015
320
Primary Genital Herpes Simplex Virus Type I in Preterm Prelabour Rupture of Membranes at 30 Weeks' Gestation. 61
26649212 2015
321
Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine. 61
25658852 2015
322
Development and evaluation of the quantitative real-time PCR assay in detection and typing of herpes simplex virus in swab specimens from patients with genital herpes. 61
26770492 2015
323
[Efficacy of polyprenyl phosphates in the experimental genital herpes model]. 61
26665428 2015
324
Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge. 61
25320297 2015
325
Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes. 61
26431156 2015
326
[IMMUNOMODULATORS IN THE TREATMENT AND PREVENTION OF HERPES VIRUS INFECTIONS]. 61
26155705 2015
327
Antiviral medication in sexually transmitted diseases. Part II: HIV. 61
25751258 2015
328
Pattern of sexually transmitted infections in a Muslim majority region of North India. 61
26392651 2015
329
Higher prevalence of sexual transmitted diseases and correlates of genital warts among heterosexual males attending sexually transmitted infection clinics (MSCs) in Jiangmen, China: implication for the up-taking of STD related service. 61
25811185 2015
330
Travel-related sexually transmitted infections. 61
26726895 2015
331
Unusual initial presentation of herpes simplex virus as inguinal lymphadenopathy. 61
25815228 2015
332
Laboratory diagnosis and epidemiology of herpes simplex 1 and 2 genital infections. 61
26086165 2015
333
Tuberculosis of the Penis: A Review of the Literature. 61
26435877 2015
334
[Infections disease update: 2014 is viral]. 61
25799655 2015
335
Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways? 61
25787060 2015
336
Preparation and characterization of bioadhesive controlled-release gels of cidofovir for vaginal delivery. 61
26300445 2015
337
History of venereal diseases from antiquity to the renaissance. 61
25969906 2015
338
Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs. 61
25837802 2015
339
Herpes genitalis and the philosopher's stance. 61
24429670 2014
340
Genital herpes and its treatment in relation to preterm delivery. 61
25392064 2014
341
Human herpes simplex virus: life cycle and development of inhibitors. 61
25749169 2014
342
Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D. 61
25138572 2014
343
Preventing herpes simplex virus in the newborn. 61
25459782 2014
344
Herpes simplex virus infection during pregnancy. 61
25454993 2014
345
Prevalence of vulvodynia and risk factors for the condition in Portugal. 61
25092355 2014
346
Herpes simplex virus and cytomegalovirus co-infection presenting as exuberant genital ulcer in a woman infected with human immunodeficiency virus. 61
25250849 2014
347
Using a two-step method to measure transgender identity in Latin America/the Caribbean, Portugal, and Spain. 61
25030120 2014
348
The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine. 61
25446827 2014
349
Genital herpes. 61
25153069 2014
350
Development and clinical evaluation of a novel fully automated qualitative PCR assay for the diagnosis of anogenital herpes simplex virus infection. 61
25128985 2014
351
[Epidemiological and clinical characteristics of anogenital dermatoses in the department of dermatology-venereology in Cotonou, Benin]. 61
25499900 2014
352
Pattern of sexually transmitted diseases in patients presenting at Ayub teaching hospital, Abbottabad. 61
25672192 2014
353
The increase of sexually transmitted infections calls for simultaneous preventive intervention for more effectively containing HIV epidemics in China. 61
25335839 2014
354
Age-related variation in sexual behaviours among heterosexual men residing in Brazil, Mexico and the USA. 61
24099979 2014
355
Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes. 61
27129009 2014
356
Evaluation of the activity and safety of CS21 barrier genital gel® compared to topical aciclovir and placebo in symptoms of genital herpes recurrences: a randomized clinical trial. 61
24010876 2014
357
A rare case of acyclovir-induced thrombocytopenia. 61
23344109 2014
358
Maternal genitourinary infections and the risk of gastroschisis. 61
25073472 2014
359
Engineering large viral DNA genomes using the CRISPR-Cas9 system. 61
25040500 2014
360
Mother-to-Child Transmission of Herpes Simplex Virus. 61
25232472 2014
361
Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine. 61
24798939 2014
362
Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes. 61
24829358 2014
363
Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine. 61
24652496 2014
364
Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. 61
25086573 2014
365
Sexual behavioral correlates with HSV-2 seroprevalence among pregnant women in Nigeria. 61
25116666 2014
366
Research gaps in defining the biological link between HIV risk and hormonal contraception. 61
24548147 2014
367
Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D. 61
24789783 2014
368
Mimicking herpes simplex virus 1 and herpes simplex virus 2 mucosal behavior in a well-characterized human genital organ culture. 61
24436451 2014
369
Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines? 61
24837838 2014
370
Status of prophylactic and therapeutic genital herpes vaccines. 61
24631871 2014
371
Acute herpetic gingivostomatitis associated with herpes simplex virus 2: report of a case. 61
25083042 2014
372
Exemplars of complex assessment and care for hospitalized older adults: genital herpes infection. 61
24942524 2014
373
Diagnosis of genital herpes simplex virus infection in the clinical laboratory. 61
24885431 2014
374
Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection. 61
24554666 2014
375
Molecular and serologic diagnostic approaches; the prevalence of herpes simplex in idiopathic men infertile. 61
25031577 2014
376
Epidemiology of genital herpes simplex virus type 1 and 2 infections in southwestern Finland during a 10-year period (2003-2012). 61
24622640 2014
377
Topical SMIP-7.7, a toll-like receptor 7 agonist, protects against genital herpes simplex virus type-2 disease in the guinea pig model of genital herpes. 61
23232327 2014
378
A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes. 61
24285847 2014
379
Topical application of polyethylenimine as a candidate for novel prophylactic therapeutics against genital herpes caused by herpes simplex virus. 61
24046087 2014
380
Aneurysms of the Sinus of Valsalva in a Patient with Behcet's Disease. 61
25988099 2014
381
Vaccination with a HSV-2 UL24 mutant induces a protective immune response in murine and guinea pig vaginal infection models. 61
24462481 2014
382
Increase male genital diseases morbidity linked to informal electronic waste recycling in Guiyu, China. 61
24271725 2014
383
The sexual health consultation as a moral occasion. 61
23336250 2014
384
Herpes simplex virus type 1 genital herpes in young women: current trend in Northern Finland. 61
24431184 2014
385
Herpes simplex virus: prevalence in placental tissue and incidence in neonatal cord blood samples. 61
24375504 2014
386
Atypical presentation of genital herpes simplex (HSV-2) in two patients with chronic lymphocytic leukemia. 61
23975187 2014
387
Chancroid, lymphogranuloma venereum, granuloma inguinale, genital herpes simplex infection, and molluscum contagiosum. 61
24559566 2014
388
Sexual behaviors and sexually transmitted infections in a nationally representative sample of women veterans and nonveterans. 61
24328438 2014
389
Management rates of sexually transmissible infections by Australian general practitioners, 2000-2012. 61
24618039 2014
390
Youth violence and connectedness in adolescence: what are the implications for later sexually transmitted infections? 61
24268359 2014
391
Recommendations from international clinical guidelines for routine antenatal infection screening: does evidence matter? 61
24685900 2014
392
Current barriers, challenges and opportunities for the development of effective STI vaccines: point of view of vaccine producers, biotech companies and funding agencies. 61
23994377 2014
393
Genomic sequences of a low passage herpes simplex virus 2 clinical isolate and its plaque-purified derivative strain. 61
24503076 2014
394
Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs. 61
24284325 2014
395
HSV-1 and HSV-2 seroprevalence in the united states among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women). 61
24926671 2014
396
Current thinking on genital herpes. 61
24335720 2014
397
Adolescents' and young women's use of a microbicide surrogate product when receiving oral sex. 61
24315715 2014
398
Genital herpes simplex virus type 2 infection in humanized HIV-transgenic mice triggers HIV shedding and is associated with greater neurological disease. 61
23990571 2014
399
Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010. 61
24136792 2014
400
Cervicovaginal HIV-1 shedding in women taking antiretroviral therapy in Burkina Faso: a longitudinal study. 61
24226060 2014
401
Asymptomatic memory CD8+ T cells: from development and regulation to consideration for human vaccines and immunotherapeutics. 61
24499824 2014
402
Helicase-primase inhibitor pritelivir for HSV-2 infection. 61
24428466 2014
403
Development of a novel approach to enhance the solubility of ftibamzone formulation. 61
26120473 2014
404
Effect of the potent antiviral 1-cinnamoyl-3,11-dihydroxymeliacarpin on cytokine production by murine macrophages stimulated with HSV-2. 61
23512754 2014
405
Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety. 61
24323471 2014
406
Agenus‘ genital herpes vaccine significantly reduces viral burden in Phase 2. 61
25580483 2014
407
Pediatric herpes simplex virus infections: an evidence-based approach to treatment. 61
24649621 2014
408
Prevalence of Trichomoniasis, Vaginal Candidiasis, Genital Herpes, Chlamydiasis, and Actinomycosis among Urban and Rural Women of Haryana, India. 61
26316979 2014
409
[A neonate with acute liver failure caused by herpes simplex infection]. 61
25248731 2014
410
Reappraisal of sexually transmitted infections in children: A hospital-based study from an urban area. 61
24958982 2014
411
Tzanck smear utilized in the diagnosis of Hailey-Hailey disease mimicking genital herpes. 61
24117014 2014
412
[Cycloferon and management of herpes virus infection]. 61
25300118 2014
413
A clinico-epidemiological study of ulcerative sexually transmitted diseases with human immunodeficiency virus status. 61
24958991 2014
414
Herpes simplex virus type 2-associated recurrent aseptic (Mollaret's) meningitis in genitourinary medicine clinic: a case report. 61
24623993 2014
415
Prevalence of Anogenital Warts in Men with HIV/AIDS and Associated Factors. 61
25317220 2014
416
Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. 61
25180698 2014
417
Comparison of risk factors for prevalent sexually transmitted infections based on attendees at two genitourinary medicine clinics in Ireland. 61
23970627 2014
418
Understanding perceptions of genital herpes disclosure through analysis of an online video contest. 61
23702459 2013
419
Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial. 61
23850416 2013
420
Apparent Rarity of Asymptomatic Herpes Cervicitis in a Woman with Intra-Uterine Contraceptive Device. 61
28299103 2013
421
Trends in seroprevalence of herpes simplex virus type 2 among non-Hispanic blacks and non-Hispanic whites aged 14 to 49 years--United States, 1988 to 2010. 61
24113408 2013
422
Antiviral medication in sexually transmitted diseases. Part I: HSV, HPV. 61
24032509 2013
423
Synthetic analogues of bovine bactenecin dodecapeptide reduce herpes simplex virus type 2 infectivity in mice. 61
24012999 2013
424
Application of shRNA-containing herpes simplex virus type 1 (HSV-1)-based gene therapy for HSV-2-induced genital herpes. 61
23845900 2013
425
Novel deletion in glycoprotein G forms a cluster and causes epidemiologic spread of herpes simplex virus type 2 infection. 61
23861013 2013
426
Generating protective immunity against genital herpes. 61
24012144 2013
427
[Syphilis. Part 1: Introduction, pathology and clinical aspects]. 61
24150827 2013
428
A not so simplex case of genital herpes. 61
24096072 2013
429
Genital Herpes. 61
23910593 2013
430
Role of polymerase chain reaction in detection of genital herpes. 61
23974589 2013
431
Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake. 61
23769419 2013
432
Genital warts in 250 Iranian patients and their high- risk sexual behaviors. 61
23981154 2013
433
Public health strategies for prevention and control of HSV-2 in persons who use drugs in the United States. 61
23647730 2013
434
Birth weight and other perinatal factors and childhood CNS tumors: a case-control study in California. 61
23562044 2013
435
Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection. 61
23572481 2013
436
[Laboratory diagnosis of genital herpes--direct immunofluorescence method]. 61
24032273 2013
437
Antiviral activity of trappin-2 and elafin in vitro and in vivo against genital herpes. 61
23637403 2013
438
Sexually transmitted diseases in a specialized STD healthcare center: epidemiology and demographic profile from January 1999 to December 2009. 61
24068122 2013
439
Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007. 61
23772935 2013
440
Sexually transmitted infections among patients with herpes simplex virus at King Abdulaziz University Hospital. 61
23898826 2013
441
Penile herpes simplex virus type 1 infection presenting two and a half years after Jewish ritual circumcision of an infant. 61
23680909 2013
442
Griffithsin protects mice from genital herpes by preventing cell-to-cell spread. 61
23536670 2013
443
Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial. 61
23434737 2013
444
[Antibiotic profylaxis in obstetrics]. 61
23869838 2013
445
Exploiting herpes simplex virus entry for novel therapeutics. 61
23752649 2013
446
Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial. 61
23970700 2013
447
The herpes simplex virus 2 UL21 protein is essential for virus propagation. 61
23487471 2013
448
[Innate immunity to infection in the lower female genital tract]. 61
23667098 2013
449
Utilization and cost of diagnostic methods for sexually transmitted infection screening among insured American youth, 2008. 61
23588123 2013
450
An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs. 61
23365421 2013
451
Genital herpes beliefs: implications for sexual health. 61
23337309 2013
452
Prevalence of Chlamydia trachomatis and herpes simplex virus type 2: Results from the 2009 to 2011 Canadian Health Measures Survey. 61
24258059 2013
453
Cultural bias in the AAP's 2012 Technical Report and Policy Statement on male circumcision. 61
23509170 2013
454
Acute cervicitis and vulvovaginitis may be associated with Cytomegalovirus. 61
23606387 2013
455
Herpes simplex virus 2 meningitis: a retrospective cohort study. 61
23494382 2013
456
Pattern of sexually transmitted infections: a profile from a sexually transmitted infections clinic of a tertiary care hospital of eastern India. 61
23919191 2013
457
Herpes simplex virus 2 : a boon to develop other sexually transmitted infections. 61
24475553 2013
458
Polyethylenimine combined with liposomes and with decreased numbers of primary amine residues strongly enhanced therapeutic antiviral efficiency against herpes simplex virus type 2 in a mouse model. 61
23298614 2013
459
Herpes simplex virus type 2 serological testing at a community court: predictors of test acceptance and seropositivity among female defendants. 61
23467289 2013
460
Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine. 61
23313657 2013
461
The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. 61
23403600 2013
462
Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. 61
23359576 2013
463
Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. 61
23378604 2013
464
Neonatal herpes simplex virus infections in Israel. 61
23334339 2013
465
Maternal and neonatal herpes simplex virus infections. 61
23303485 2013
466
Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2. 61
23755244 2013
467
Recent developments in anti-herpesvirus drugs. 61
23596085 2013
468
Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes. 61
22743007 2013
469
High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo. 61
23468943 2013
470
Application and tolerability of Herpotherm(®) in the treatment of genital herpes. 61
23776340 2013
471
In vivo evaluation of antiviral efficacy against genital herpes using mouse and guinea pig models. 61
23821278 2013
472
[Structural changes of the adrenal cortex in experimental genital herpes virus infection]. 61
24707741 2013
473
Sex differences in health care provider communication during genital herpes care and patients' health outcomes. 61
24015854 2013
474
Effect of genital herpes on cervicovaginal HIV shedding in women co-infected with HIV AND HSV-2 in Tanzania. 61
23516595 2013
475
Herpes genitalis - Topical zinc sulfate: An alternative therapeutic and modality. 61
23919052 2013
476
An indole alkaloid from a tribal folklore inhibits immediate early event in HSV-2 infected cells with therapeutic efficacy in vaginally infected mice. 61
24167591 2013
477
[Herpes simplex]. 61
23431880 2013
478
Methods for screening and profiling inhibitors of herpes simplex viruses. 61
23821277 2013
479
Neonatal case of herpes simplex virus encephalitis after delivery from a woman whose genital herpes simplex virus infection had been treated with acyclovir. 61
24419718 2013
480
Resiquimod, a topical drug for viral skin lesions and skin cancer. 61
23205468 2013
481
Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong Kong. 61
23990994 2013
482
Sexually transmitted infections and male circumcision: a systematic review and meta-analysis. 61
23710368 2013
483
Sexually transmitted diseases in Poland in 2011. 61
24040734 2013
484
Etiology of genital ulcer disease in a sexually transmitted infection reference center in Manaus, Brazilian Amazon. 61
23704961 2013
485
Arginine inactivates human herpesvirus 2 and inhibits genital herpesvirus infection. 61
23042569 2012
486
Therapeutic vaccine for treatment of genital herpes enters phase 2. 61
23980267 2012
487
Skin and Mucocutaneous Manifestations: Useful Clinical Predictors of HIV/AIDS. 61
23373031 2012
488
Genital herpes zoster as a consequence of cancer chemotherapy-induced immunosuppression: report of a case. 61
22398883 2012
489
Prevalence and characteristics of herpes simplex virus type-2 coinfection in veterans with hepatitis C. 61
22395713 2012
490
The challenge of developing a herpes simplex virus 2 vaccine. 61
23252387 2012
491
A vaccine strategy that protects against genital herpes by establishing local memory T cells. 61
23075848 2012
492
Type-specific identification of anogenital herpes simplex virus infections by use of a commercially available nucleic acid amplification test. 61
22875892 2012
493
Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88. 61
23018456 2012
494
'Herpes present' reported in a routine cervical cytology and how to deal with it. 61
23036743 2012
495
A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. 61
23041125 2012
496
Poly (4-styrenesulfonic acid-co-maleic acid) is an entry inhibitor against both HIV-1 and HSV infections - potential as a dual functional microbicide. 61
22940611 2012
497
Sexual health and the Rugby World Cup 2011: a cross-sectional study of sexual health clinics in New Zealand. 61
23380197 2012
498
Herpes genitalis without frontiers: from clinical aspects to viral identification.